

Emergencies in Hematology and Oncology



Thorvardur R. Halfdanarson, MD; William J. Hogan, MBBCh;
and Bo E. Madsen, MD, MPH

CME Activity

Target Audience: The target audience for *Mayo Clinic Proceedings* is primarily internal medicine physicians and other clinicians who wish to advance their current knowledge of clinical medicine and who wish to stay abreast of advances in medical research.

Statement of Need: General internists and primary care physicians must maintain an extensive knowledge base on a wide variety of topics covering all body systems as well as common and uncommon disorders. *Mayo Clinic Proceedings* aims to leverage the expertise of its authors to help physicians understand best practices in diagnosis and management of conditions encountered in the clinical setting.

Accreditation: Mayo Clinic College of Medicine and Science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Statement: Mayo Clinic College of Medicine and Science designates this journal-based CME activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*.[™] Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Credit Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Objectives: On completion of this article, you should be able to (1) recognize both common and uncommon hematologic and oncological emergencies in patients with cancer; (2) identify which patients need emergent or urgent initiation of therapy and admission to the hospital for an optimal outcome, and (3) promptly initiate the appropriate therapy for life-threatening complications of both the cancer itself and the therapy directed against the cancer.

Disclosures: As a provider accredited by ACCME, Mayo Clinic College of Medicine and Science (Mayo School of Continuous Professional

Development) must ensure balance, independence, objectivity, and scientific rigor in its educational activities. Course Director(s), Planning Committee members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published in course materials so that those participants in the activity may formulate their own judgments regarding the presentation.

In their editorial and administrative roles, William L. Lanier, Jr, MD, Terry L. Jopke, Kimberly D. Sankey, and Nicki M. Smith, MPA, have control of the content of this program but have no relevant financial relationship(s) with industry.

The authors report no competing interests.

Method of Participation: In order to claim credit, participants must complete the following:

1. Read the activity.
2. Complete the online CME Test and Evaluation. Participants must achieve a score of 80% on the CME Test. One retake is allowed. Visit www.mayoclinicproceedings.org, select CME, and then select CME articles to locate this article online to access the online process. On successful completion of the online test and evaluation, you can instantly download and print your certificate of credit.

Estimated Time: The estimated time to complete each article is approximately 1 hour.

Hardware/Software: PC or MAC with Internet access.

Date of Release: 4/1/2017

Expiration Date: 3/31/2019 (Credit can no longer be offered after it has passed the expiration date.)

Privacy Policy: <http://www.mayoclinic.org/global/privacy.html>

Questions? Contact dietsupport@mayo.edu.

From the Division of Medical Oncology (T.R.H.), Division of Hematology (W.J.H.), and Department of Emergency Medicine (B.E.M.), Mayo Clinic, Rochester, MN.

Abstract

The development of medical emergencies related to the underlying disease or as a result of complications of therapy are common in patients with hematologic or solid tumors. These oncological emergencies can occur as an initial presentation or in a patient with an established diagnosis and are encountered in all medical care settings, ranging from primary care to the emergency department and various subspecialty environments. Therefore, it is critically important that all physicians have a working knowledge of the potential oncological emergencies that may present in their practice and how to provide the most effective care without delay. This article reviews the most common oncological emergencies and provides practical guidance for initial management of these patients.

© 2017 Mayo Foundation for Medical Education and Research ■ *Mayo Clin Proc.* 2017;92(4):609-641

Cancer is expected to be diagnosed in more than 1.6 million people in the United States in 2017. A small percentage of these patients will experience an emergent cancer-related complication at some point during the disease course. For some patients, an emergent complication is the first manifestation of the cancer.¹ Given

the large number of patients with active cancer, many practicing physicians can expect to encounter patients with a cancer-related emergency. It is therefore imperative that practitioners, especially primary and emergency care physicians, are able to rapidly recognize and effectively manage patients with these complications. Emergencies in hematology

and oncology can be broadly classified as conditions resulting from the cancer itself and complications related to therapy directed against the malignant disease, although there can be some overlap between the 2 categories. The emergencies can also be classified according to organ systems, which is the approach taken in this review.

METABOLIC EMERGENCIES

Hypercalcemia of Malignancy

Hypercalcemia is common in patients with advanced cancer and has been reported in up to 30% of patients with cancer.² The incidence varies greatly among cancer types, and hypercalcemia is most commonly associated with multiple myeloma, non–small cell lung cancer (especially squamous cell cancer), renal cell carcinoma, breast cancer, non-Hodgkin lymphoma, and leukemia but can also be seen in multiple other malignant disorders.³ The presence of hypercalcemia in a patient with cancer is an adverse prognostic factor predicting a shorter survival, but effective therapy, both for the hypercalcemia and the underlying cancer, may improve outcomes.⁴⁻⁷

Pathophysiology. The pathophysiology of hypercalcemia of malignancy can be divided into 3 major categories.⁸ The first category, often called humoral hypercalcemia of malignancy, usually results from tumor production of parathyroid hormone–related peptide (PTHrP) and less commonly intact parathyroid hormone (PTH). It is the most common underlying cause of hypercalcemia of malignancy. The second category is hypercalcemia from bone destruction and dissolution (osteolysis) from extensive bone metastases. The third and least common category is excess production of vitamin D analogues by the malignant cells. Humoral hypercalcemia of malignancy accounts for up to 80% of hypercalcemia that occurs in patients with cancer and is the dominant cause in patients with solid tumors.^{2,9} Structurally, PTHrP is closely related to PTH and exerts many of the functions of PTH itself. It binds to receptors on osteoblasts and stimulates their activity through receptor activator of nuclear factor κ B ligand (RANKL) signaling. This process in turn stimulates the osteoclasts, increasing their activation and proliferation

and subsequently releases calcium into the circulation.^{8,10,11} The presence of elevated PTHrP in humoral hypercalcemia of malignancy portends poorer prognosis and decreased response to therapy with bisphosphonates.¹²⁻¹⁴ Osteolysis as a cause of hypercalcemia is commonly seen in patients with breast cancer, lung cancer, and multiple myeloma. Several cytokines have been implicated in the pathogenesis of cancer-induced osteolysis, including tumor necrosis factor, macrophage inflammatory protein 1a, and lymphotoxin.^{15,16} Local production of PTHrP may also result in osteolysis, which is in part mediated through the RANKL pathway.^{17,18} Extrarenal production of 1,25-dihydroxyvitamin D (calcitriol) can occur in patients with both Hodgkin and non-Hodgkin lymphomas as well as nonmalignant granulomatous diseases such as sarcoidosis.^{19,20} Very rarely, ectopic production of PTH by tumors causes hypercalcemia.²¹ Hypercalcemia of malignancy can also be exacerbated by factors unrelated to the malignant disorder itself such as the intake of calcium, vitamin D, lithium, and thiazides. Thiazides are thought to reduce urinary calcium excretion as a result of increased passive calcium reabsorption at the proximal tubule and increased distal reabsorption at a thiazide sensitive site.

Clinical Presentation and Diagnosis. Hypercalcemia is caused by either primary hyperparathyroidism or malignant disease more than 90% of the time. Therefore, it is important to distinguish between these 2 entities early on. In hypercalcemia associated with cancer, there are frequently overt signs of malignant disease at presentation. Hypercalcemia can cause a multitude of nonspecific symptoms. Lethargy, confusion, anorexia, nausea, constipation, polyuria, and polydipsia are all common symptoms of hypercalcemia, and the severity may correlate with the degree of hypercalcemia and the rapidity of onset.^{22,23} Severe hypercalcemia, especially of rapid onset, may cause cardiac dysrhythmias such as bradycardia, shortening of the QT interval, and even cardiac arrest.²⁴ The physical examination is generally not helpful in making the diagnosis but can reveal signs of volume depletion and impaired cognitive function as well as signs of the underlying cancer such as enlarged lymph nodes.

TABLE 1. Treatment of Hypercalcemia

Intervention	Dosage	Comments
Saline	250-500 mL/h IV until euvolemic and 100-150 mL/h IV after volume repletion is achieved. Can start by giving an 1- to 2-L initial bolus over 1 h if hypovolemic	The rate of infusion should be adjusted for the cardiovascular status of the patient
Pamidronate	60-90 mg IV over 2-4 h	Use with caution in renal insufficiency. Onset of action may take days
Zoledronic acid	4 mg IV over 15 min	Use with caution in renal insufficiency. Onset of action may take days
Calcitonin	4-8 IU/kg SC or IV every 12 h	Rapid onset of action but short-lived
Glucocorticoids	Prednisone, 60 mg/d PO; hydrocortisone, 100 mg every 6 h IV	Useful for hypercalcemia from calcitriol overproduction and in multiple myeloma
Denosumab	120 mg SC weekly for 4 wk, then every 4 wk	Safe in renal insufficiency but doses should be reduced. Can cause severe hypocalcemia
Furosemide	20-40 mg IV	Only for patients with volume overload after volume expansion

IV = intravenously; PO = orally; SC = subcutaneously.

The diagnosis of hypercalcemia is confirmed by measuring the serum calcium level. Ionized calcium measurement is the preferred method of diagnosis, if available. If total serum calcium is measured, a correction needs to be made for the albumin level. The corrected calcium level is calculated as follows: corrected calcium = measured total calcium + $[0.8 \times (4.0 - \text{albumin})]$.

Intact PTH is usually low in hypercalcemia of malignancy and can be helpful as a diagnostic tool, but the results may not be available immediately. An elevated PTH level in a patient with known malignant disease suggests either a coexisting hyperparathyroidism or a PTH-producing tumor. Measurements of PTHrP are generally not needed but may help elucidate the etiology of the hypercalcemia, and elevated levels may predict response to bisphosphonate therapy and predict inferior survival.¹²⁻¹⁴ One study reported less response to bisphosphonates and higher risk of recurrent hypercalcemia in patients with PTHrP levels greater than 12 pmol/L.²⁵ A low serum chloride level (<100 mEq/L [to convert to mmol/L, multiply by 1.0]) can point to cancer as the underlying cause.²⁶ All patients with severe hypercalcemia should undergo electrocardiography.

Treatment. Untreated, severe hypercalcemia is a life-threatening entity that calls for immediate intervention for optimal results in patients who are candidates for active therapy. Physicians should not delay starting therapy

while awaiting laboratory results such as PTHrP level. Not all patients with hypercalcemia need urgent treatment, and many patients with mild hypercalcemia can be managed as outpatients. Patients with more severe and symptomatic hypercalcemia are usually hospitalized for inpatient therapy. In some cases of advanced cancer, specific therapy may not be recommended if the underlying malignant disease is otherwise untreatable.^{6,27} The patient's goals and wishes should always be considered before instituting therapy. Best supportive care at home, often with the help of hospice care professionals, may be appropriate for patients who have no effective treatment options remaining for their cancer or who do not wish to receive any further therapy.

The following recommendations apply to patients with severe hypercalcemia (calcium level >14 mg/dL [> 3.5 mmol/L]) and/or very symptomatic hypercalcemia. Table 1 lists the treatment options for hypercalcemia. The first step in the management is the administration of intravenous (IV) fluids because patients are often profoundly hypovolemic, often in the order of 5 to 10 L. Volume expansion will increase the renal clearance of calcium and lower calcium levels. Normal saline (0.9% sodium chloride) is the preferred IV fluid. Patients may require large volumes of normal saline, and 1000 to 2000 mL should be given in the first hour of fluid resuscitation. Larger volumes may be needed initially in hypotensive patients. After the initial bolus

of normal saline, an IV infusion of 250 to 500 mL/h can be used until urine output and euolemia are established.

Calcitonin can lower calcium levels by inhibiting osteoclasts and can enhance urinary excretion of calcium.²⁸ The onset of action of calcitonin is quick, but tachyphylaxis develops within days of use.^{29,30} It is therefore of most use when a prompt reduction in calcium levels is required. Calcitonin is given as a subcutaneous injection, and no dosage adjustment is needed in patients with renal insufficiency.³¹ The use of loop diuretics is strongly discouraged because they may exacerbate the hypovolemia and therefore impair calcium excretion.³² Loop diuretics should be reserved only for patients with clinical evidence of volume overload. Bisphosphonates are the mainstay of the treatment and are able to control the hypercalcemia in most patients.³³⁻³⁶ Bisphosphonates block osteoclastic bone resorption, but the onset of action is slow and it may take 2 to 3 days to see a full effect. The most commonly used bisphosphonates in the United States are pamidronate (60-90 mg IV over 2-4 hours) and zoledronic acid (4 mg IV over 15 minutes), but zoledronic acid is often preferred because it can be given as a short IV infusion and may be more effective than pamidronate.³³ Ibandronate is also effective but infrequently used in the United States.^{37,38} Bisphosphonates are potentially nephrotoxic and should be used with caution in patients with renal insufficiency.

Glucocorticoids are useful in patients whose hypercalcemia is driven by overproduction of calcitriol because they inhibit the conversion of calcidiol to calcitriol.^{30,39} Commonly used glucocorticoids include prednisone (60 mg orally daily) and hydrocortisone (100 mg IV every 6 hours). Gallium nitrate and mithramycin (plicamycin) have been used in the past but are not readily available now and have been replaced by safer agents.^{40,41} Denosumab, a humanized monoclonal antibody directed against the RANKL that inhibits osteoclast activation and function, was recently approved for use in hypercalcemia of malignancy. Denosumab has been used successfully in hypercalcemia refractory to bisphosphonate therapy.^{42,43} In a single-arm trial in patients who remained hypercalcemic after bisphosphonate therapy, denosumab

lowered the calcium levels in most patients and had a prolonged duration of response.⁴⁴ Denosumab was given as 120 mg subcutaneously weekly for 4 weeks and then every 4 weeks thereafter. It is well tolerated but may result in symptomatic hypocalcemia.^{43,44} Denosumab can safely be given to patients with renal insufficiency, but the risk of hypocalcemia may be increased.⁴⁵ The dose should be reduced in patients with renal insufficiency, but the optimal dose has not been established. A fixed single dose of 60 mg subcutaneously has resulted in symptomatic hypocalcemia, and a weight-based dose of 0.3 mg/kg may be a safer alternative followed by careful monitoring and repeated administration in a week if needed.⁴⁵ The calcimimetic cinacalcet has been reported to lower serum calcium levels in patients with hypercalcemia secondary to PTH production of parathyroid carcinoma but is not recommended in hypercalcemia of other etiologies.⁴⁶ Hemodialysis can be used in refractory cases and situations in which other methods cannot be used safely but should be considered as a last-resort therapy.^{47,48} Effective systemic therapy or radiotherapy for the underlying disease, if available, can further help decrease the serum calcium levels.

Tumor Lysis Syndrome

Tumor lysis syndrome (TLS) is a constellation of metabolic derangements resulting from the death of neoplastic cells which then release their intracellular contents into the circulation.⁴⁹ It is most commonly seen in patients with very aggressive hematologic cancers such as high-grade lymphomas and acute leukemias.^{50,51} Tumor lysis syndrome is occasionally seen in patients with aggressive solid tumors such as small cell carcinoma of the lung.⁵² It usually occurs after effective therapy has begun but can also occur spontaneously.⁵³ It is most commonly seen after the initiation of cytotoxic chemotherapy but can also result from glucocorticoid therapy for lymphoma, endocrine therapy for advanced breast cancer, various targeted agents, and radiotherapy for radiosensitive malignant diseases.⁵⁴

Pathophysiology. Tumor lysis syndrome is caused by massive release of intracellular contents into the bloodstream at the time of the death of neoplastic cells.^{50,55} The catabolism

of nucleic acids results in hyperuricemia. High concentrations of uric acid will lead to crystallization within renal tubules and tubular obstruction resulting in acute kidney injury. The renal failure is further exacerbated by hypovolemia leading to acute tubular necrosis. Elevated levels of uric acid may also lead to kidney injury independently of uric acid crystal formation, possibly secondary to alteration in the intrarenal hemodynamics.⁵⁶ The release of organic and inorganic phosphates from the neoplastic cells leads to hyperphosphatemia, which in turn leads to hypocalcemia and precipitation of calcium phosphate and nephrocalcinosis. Hyperkalemia is frequently the first manifestation of TLS, may occur within a few hours after therapy is started, and can result in life-threatening cardiac arrhythmias.⁵⁷

Clinical Presentation and Diagnosis. Patients with TLS can present with symptoms (clinically evident TLS) or with abnormal laboratory test results in the absence of symptoms (laboratory TLS).⁵⁸ The presenting symptoms of TLS are nonspecific, and a high index of suspicion is needed for a timely diagnosis. Decreased urine output followed by symptoms of uremia and volume overload may occur. Seizures, arrhythmias, and even sudden death are known presentations of TLS.

Typical laboratory findings include elevated uric acid, phosphorus, potassium, and lactate dehydrogenase levels as well as low calcium concentrations. The diagnostic criteria and definition of TLS have evolved, but the most commonly used definition is the that of Cairo and Bishop⁵⁹ (Table 2).

Risk Stratification. The risk factors for development of TLS are well known.⁵¹ The risk is determined by the type of cancer as well as the treatment given and underlying conditions. Tumor-specific risk factors include high tumor burden, high tumor grade with rapid cell turnover, and treatment-sensitive tumor. Age, preexisting renal impairment, and concomitant use of drugs known to increase uric acid are patient-specific risk factors. Aspirin, alcohol, thiazide diuretics, and caffeine are known to increase uric acid levels. The risk can be categorized on the basis of the characteristics of the underlying

TABLE 2. Cairo-Bishop Classification of Laboratory and Clinical Tumor Lysis Syndrome

Laboratory tumor lysis syndrome
Uric acid ≥ 8 mg/dL (≥ 476 $\mu\text{mol/L}$) or 25% increase from baseline
Potassium ≥ 6.0 mEq/L (≥ 6.0 mmol/L) or 25% increase from baseline
Phosphorus ≥ 4.5 mg/dL (≥ 1.45 mmol/L) or 25% increase from baseline
Calcium ≤ 7 mg/dL (≤ 1.75 mmol/L) or 25% decrease from baseline
Clinical tumor lysis syndrome
Presence of laboratory tumor lysis syndrome and one or more of the following criteria
Creatinine ≥ 1.5 times the upper limit of normal
Cardiac arrhythmia
Seizure
Sudden death

Adapted from *Br J Haematol*,⁵⁹ with permission. Copyright ©1999-2017 John Wiley & Sons, Inc. All rights reserved.

malignant disease and patient characteristics (Table 3).⁵³

Prevention and Treatment. Tumor lysis syndrome can often be prevented, and it is therefore of utmost importance to identify patients at risk and initiate prophylactic therapy because TLS is associated with increased mortality and morbidity as well as increased cost.^{51,60-63} Adequate hydration and the appropriate use of uric acid-lowering (uricosuric) drugs can effectively reduce uric acid levels and reduce the risk of renal injury. The choice of uricosuric drugs depends on the risk of TLS for the given patient (Tables 3 and 4). The most commonly used drugs are allopurinol and rasburicase. Allopurinol is an inhibitor of xanthine oxidase and reduces the production of uric acid by decreasing the rate of conversion of hypoxanthine to xanthine and xanthine to uric acid. Both xanthine and hypoxanthine are more water soluble than uric acid. Allopurinol does not facilitate the breakdown of the uric acid that has already been produced. Allopurinol is an appropriate uricosuric drug in patients with low or intermediate risk of TLS. The prophylactic dose of allopurinol is 200 to 400 mg/m² daily in 1 to 3 divided doses, up to a maximum of 800 mg daily.⁵¹ Febuxostat is a selective inhibitor of xanthine oxidase that is approved for treatment of gout. It has fewer drug-drug interactions than allopurinol, and dose adjustment is not needed in patients with mild to moderate renal impairment.⁶⁴ Febuxostat has been compared to allopurinol

TABLE 3. Risk Stratification of Tumor Lysis Syndrome and Recommendations for Prophylaxis^{a,b}

Risk category	Malignant disease	Prophylaxis
Low-risk disease	Solid tumor ^c Multiple myeloma CML CLL ^d Indolent NHL Hodgkin lymphoma AML (WBC <25,000/ μ L and LDH <2 \times ULN)	Monitoring (daily laboratory tests) Intravenous hydration (3 L/m ² daily) Consider allopurinol
Intermediate-risk disease	AML (WBC 25,000-100,000/ μ L) AML (WBC <25,000/ μ L and LDH \geq 2 \times ULN) Intermediate-grade NHL (LDH \geq 2 \times ULN) ALL (WBC <100,000/ μ L and LDH <2 \times ULN) Burkitt lymphoma (LDH <2 \times ULN) Lymphoblastic NHL (LDH <2 \times ULN)	Monitoring (laboratory tests every 8-12 h) Intravenous hydration (3 L/m ² daily) Allopurinol for up to 7 d
High-risk disease	ALL (WBC \geq 100,000/ μ L and/or LDH \geq 2 \times ULN) Burkitt lymphoma (stages III/IV and/or LDH \geq 2 \times ULN) Lymphoblastic NHL (stages III/IV and/or LDH \geq 2 \times ULN) IRD with renal dysfunction and/or renal involvement IRD with elevated uric acid, potassium, and/or phosphate	Monitoring (laboratory tests every 6-8 h) Intravenous hydration (3 L/m ² daily) Rasburicase (consider 3 mg fixed dose)

^aALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CLL = chronic lymphoid leukemia; CML = chronic myeloid leukemia; IRD = intermediate-risk disease; LDH = lactate dehydrogenase; NHL = non-Hodgkin lymphoma; ULN = upper limit of normal; WBC = white blood cell count.

^bSI conversion factors: To convert WBC to $\times 10^9/L$, multiply by 0.001.

^cRare solid tumors such as small cell carcinoma, germ cell tumors, or others with bulky or advanced disease can be classified as IRD.

^dCLL treated with fludarabine and rituximab and/or those with a high WBC ($\geq 50 \times 10^9/L$) can be classified as IRD.

Adapted from *Br J Haematol*,⁵³ with permission. Copyright ©1999-2017 John Wiley & Sons, Inc. All rights reserved.

for prevention of TLS. It was found to be more effective in lowering uric acid levels, but it is uncertain if it reduces clinically important TLS, at least when compared with high doses of allopurinol, and its role in management of TLS needs to be determined with further trials.⁶⁵ The dose of febuxostat is 120 mg daily. Rasburicase is a recombinant form of urate oxidase and metabolizes uric acid to allantoin, which is much more soluble than uric acid.⁶⁶ The use of rasburicase is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Unlike allopurinol, rasburicase also lowers already formed uric acid. Rasburicase is generally reserved as prophylaxis for patients at high risk of TLS or patients already experiencing TLS. Rasburicase is effective as TLS prophylaxis in both adults and children.⁶⁷⁻⁷¹ Despite the efficacy of rasburicase in lowering uric acid levels and preventing TLS, it has not been proven to be superior to allopurinol in preventing clinical TLS and related complications.⁷²⁻⁷⁴ Despite the lack of data on hard clinical end points, treatment with

rasburicase is recommended in all patients with high risk of TLS. The recommended dose of rasburicase is 0.2 mg/kg once daily for up to 5 to 7 days, but lower doses and shorter duration of therapy are commonly used. A single fixed dose of 3 mg has been studied and seems to be very effective in preventing TLS, and the dose can be repeated later if needed.⁷⁵⁻⁷⁸ Recently published guidelines from the British Committee for Standards in Haematology have endorsed the use of a single fixed 3-mg dose of rasburicase as adequate prophylactic therapy for TLS in the absence of established clinical or laboratory TLS.⁵¹ The dose should be repeated daily if there is any evidence of progressive TLS, and if clinical TLS develops on the fixed-dose regimen, the treatment should be changed to the standard dose of 0.2 mg/kg per day. Urinary alkalization is not recommended because it can decrease the solubility of xanthine. Normal saline is recommended as the IV fluid of choice in the management of TLS.

Patients with established TLS should receive multidisciplinary care to ensure the

TABLE 4. Treatment of Metabolic Abnormalities Associated With Tumor Lysis Syndrome

Abnormality	Intervention	Dose	Comments
Renal insufficiency and hypovolemia	Intravenous fluids	NS 3 L/m ² /d (200 mL/kg/d)	Use with caution if history of CHF
	Dialysis	NA	Use in anuria and severe oliguria with volume overload
Hyperuricemia	Allopurinol	200-400 mg/m ² /d PO in divided doses every 8-12 h Commonly used doses include 600 mg initially followed by 300 mg daily IV 200-400 mg/m ² /d in 2-3 divided doses	Reduce dose in renal failure Multiple drug interactions (6-mercaptopurine and azathioprine) IV allopurinol should only be used in patients unable to take medications by mouth Does not lower uric acid already formed
	Rasburicase	Flat fixed dose of 3 mg IV 0.2 mg/kg/d IV for up to 7 d for established TLS	Contraindicated in G6PD deficiency Transfer blood samples to the laboratory on ice Risk of sensitization and allergic reactions Expensive
	Febuxostat	120 mg PO daily	Expensive Uncertain if more effective than allopurinol No need to adjust doses in mild to moderate renal insufficiency
Hyperphosphatemia (phosphate >6.5 mg/mL [>2.1 mmol/L])	Minimize phosphate intake	NA	Low phosphorus diet Phosphorus-free IV fluids
	Phosphate binders (aluminum hydroxide) Dialysis	PO 50-150 mg/kg/d NA	May interfere with drug absorption If no response to medical therapy
Hyperkalemia	Insulin (regular)	IV 10 U	...
	Dextrose (50%)	IV 50-100 mL	...
	Calcium gluconate (10%; 10% = 100 mg/mL)	IV 10 mL (1000 mg)	Do not give with bicarbonate Use if arrhythmias or ECG changes Can repeat as needed
	Sodium bicarbonate	IV 150 mEq in 1 L of D5W over 2-4 h	Use if acidosis Can repeat in 30 min
	Sodium polystyrene sulfonate Albuterol Dialysis	PO 15-30 g every 6 h (can be used rectally) Inhaled 10-20 mg NA	Can be given with sorbitol For severe hyperkalemia Severe hyperkalemia not responsive to other measures Renal failure Volume overload
Hypocalcemia	Calcium gluconate (10%; 10% = 100 mg/mL)	IV 10 mL (1000 mg) as an infusion over 10-20 minutes	Only if symptomatic Repeat as necessary Caution in patients with severe hyperphosphatemia

CHF = congestive heart failure; D5W = 5% dextrose in water; ECG = electrocardiogram; G6PD = glucose-6-phosphate dehydrogenase; IV = intravenous; NA = not applicable; NaHCO₃ = sodium bicarbonate; NS = normal saline; PO = orally; TLS = tumor lysis syndrome.

best possible outcome. Frequent monitoring is essential, and patients are often transferred to intensive care units for therapy. High urine output is maintained with hydration and careful monitoring of fluid balance. The optimal rate of fluid replacement remains unknown, but 3 L/m² every 24 hours is reasonable.^{50,79} Alkalinization of the urine is not recommended, and diuretics should only be used for volume overload and then with extreme caution.⁵⁵ Rasburicase is the uricosuric agent of choice in established clinical TLS and should be used in a dose of 0.2 mg/kg daily for up to 7 days.⁵¹ Hyperkalemia should be treated aggressively. Asymptomatic hypocalcemia should not be treated, but symptomatic hypocalcemia (tetany, arrhythmia, or seizures) should be treated carefully with IV calcium gluconate with the aim of controlling the symptoms but not normalizing the serum calcium level. Restriction of phosphate intake and phosphate binders may be used for hyperphosphatemia, but severe elevations in phosphate may require hemodialysis. Other indications for dialysis are severe hyperkalemia, severe oliguria or anuria, and volume overload.

Lactic Acidosis

Lactic acidosis is a rare complication of cancer and is most often seen in patients with aggressive hematologic cancers and less commonly with high-grade solid tumors.⁸⁰⁻⁸² The pathogenesis of lactic acidosis in cancer is poorly understood and likely involves both increased lactate production by the tumor and decreased clearance by the liver. Many, but not all, patients have extensive liver metastases, and some patients may have thiamine deficiency.^{80,81,83} Therapy for cancer-associated lactic acidosis includes intensive supportive care and therapy directed at the underlying malignant disorder but is frequently ineffective, and death is usually imminent. Chemotherapy is appropriate in patients with chemotherapy-sensitive tumors, but long-term survival is rare.^{80,82}

Hyponatremia

Hyponatremia is the most common metabolic disturbance in patients with cancer, affecting up to 60% toward the end of life and associated with inferior survival.⁸⁴⁻⁸⁶ The etiology

of hyponatremia in these patients is multifactorial and includes the syndrome of inappropriate antidiuretic hormone secretion, either from the cancer itself or from drugs, hypovolemia, and salt-wasting nephropathy.^{87,88} Most cases of hyponatremia in patients with cancer are mild to moderate and either require no therapy or can be treated in the outpatient setting. Symptoms of hyponatremia include headache, nausea, vomiting, lethargy, confusion, and seizures.⁸⁹ Patients are usually hypovolemic or euvolemic on examination. Severe symptomatic hyponatremia should be corrected slowly with the aim of an increase in the plasma sodium level of 4 to 6 mEq/L (to convert to mmol/L, multiply by 1.0) per day to prevent osmotic demyelination.^{90,91} Patients with severe hyponatremia presenting with altered mental status or seizures are typically treated with hypertonic saline (3%) given as 3 mL/kg over 30 to 60 minutes, which will rapidly increase the serum sodium by 4 to 6 mEq/L.

Hypoglycemia

Hypoglycemia is a rare complication of cancers seen mainly in patients with neuroendocrine tumors that produce insulin (insulinomas).⁸⁷ Patients with metastatic malignant insulinoma can have severe hypoglycemia. Small, localized benign insulinomas can cause intermittent symptomatic hypoglycemia and are often very difficult to diagnose. Hypoglycemia is rarely seen in nonneuroendocrine cancers but occasionally occurs in end-stage liver failure from extensive hepatic replacement by tumor. Typical symptoms of hypoglycemia are palpitations, tremulousness, diaphoresis, anxiety, and hunger. Further neuroglycopenic symptoms may follow, such as confusion, loss of consciousness, and seizures. If tumor-induced hypoglycemia is suspected, plasma insulin, proinsulin, C-peptide, and β -hydroxybutyrate levels should be measured in addition to glucose. The initial treatment of hypoglycemia in cancer is no different than treatment of hypoglycemia in general. Symptomatic hypoglycemia in an alert patient can be treated with oral fast-acting carbohydrates, but severe symptomatic hypoglycemia requires IV administration of dextrose. A common dose is 25 g of 50% dextrose given as a slow IV push.

Patients with symptomatic hypoglycemia from metastatic insulin-producing neuroendocrine tumors usually require further therapy including continuous infusion of dextrose, diazoxide, and octreotide followed by tumor-directed therapy.⁹²

Adrenal Insufficiency

Adrenal insufficiency may result from a near-complete replacement of the adrenal glands by malignant tumor or secondary to therapy. Despite the adrenal glands being common sites for metastases, adrenal insufficiency from tumor replacement is rare. Iatrogenic adrenal insufficiency is much more common. Prolonged therapy with glucocorticoids will result in adrenal suppression, and a sudden cessation of such therapy can lead to acute adrenal insufficiency. Megestrol acetate, which is commonly used for cancer cachexia, can cause adrenal insufficiency while patients are taking the drug as well as an acute exacerbation when it is abruptly stopped.⁹³ Furthermore, megestrol acetate is associated with adrenal insufficiency in acutely ill individuals.⁹⁴ Mitotane, a rarely used adrenolytic drug indicated for the management of adrenocortical carcinoma, invariably results in adrenal insufficiency, and all patients taking mitotane also need to take replacement corticosteroids.⁹⁵ Typical signs and symptoms of adrenal insufficiency include weakness, anorexia, nausea, vomiting, and hypotension. Hyponatremia, often accompanied by hyperkalemia, is a common laboratory finding. Circulatory collapse and shock may occur, especially if there is another intercurrent illness such as an infection. If adrenal crisis is suspected, therapy should be started without delay.⁹⁶ Normal saline, 1 to 2 L in the first hour, followed by an infusion should be given. Hypotonic fluids should be avoided because they may exacerbate the hyponatremia. Glucocorticoids can reverse the adrenal crisis and should be given once the diagnosis is suspected. Dexamethasone (4 mg IV bolus) is preferred because it does not interfere with cortisol assays. Hydrocortisone at 100 mg IV can also be given but interferes with the cortisol assay. Hydrocortisone at a dose of 50 mg IV is an appropriate maintenance therapy until the situation has stabilized.

HEMATOLOGIC EMERGENCIES

Hyperviscosity Due to Monoclonal Proteins

Hyperviscosity is defined as an intrinsic resistance of fluid to flow. It can be seen in disorders in which there is increased production of monoclonal proteins such as in multiple myeloma and Waldenström macroglobulinemia (WM). Blood viscosity can be increased secondary to an excess of either cellular or acellular elements.⁹⁷

Pathophysiology. Excessive production of immunoglobulins can lead to increased blood viscosity. Of all the dysproteinemic disorders, WM is the most likely to cause hyperviscosity. Earlier studies reported that up to 30% of patients experienced hyperviscosity.⁹⁸ The prevalence seems to be declining because the disease is now being diagnosed at earlier stages. The IgM monoclonal protein produced by WM is a large pentamer that is 80% intravascular and can therefore profoundly affect the blood viscosity.⁹⁹ IgG and IgA are much less likely to cause hyperviscosity, and hyperviscosity is uncommonly seen in multiple myeloma.¹⁰⁰ The levels of monoclonal protein that cause hyperviscosity symptoms can vary considerably between patients but are relatively consistent and reproducible in an individual patient. In general, symptoms of hyperviscosity are unlikely with serum viscosity of less than 4 cP, which usually corresponds to IgM levels of 3 g/dL (to convert to g/L, multiply by 10).¹⁰¹⁻¹⁰³ According to one study, most symptomatic patients had viscosity above 8 cP.¹⁰⁴ High concentrations of monoclonal protein result in impaired microcirculatory blood flow and subsequent ischemia causing the characteristic symptoms of hyperviscosity. Because the relationship between a monoclonal protein and symptoms of hyperviscosity is not linear, once clinical symptoms of hyperviscosity occur, even a slight further increase in the concentration of monoclonal protein can dramatically worsen symptoms, and conversely, a modest reduction in the concentration can greatly relieve symptoms.

Clinical Presentation and Diagnosis. The onset of the symptoms of hyperviscosity syndromes is usually insidious. Symptoms from

TABLE 5. Clinical Manifestations of Hyperviscosity

Central nervous system
Headache
Dizziness and vertigo
Seizures
Concentrating difficulties
Impaired level of consciousness
Tinnitus and deafness
Ophthalmologic
Blurry vision or loss of vision
Diplopia
Retinal vein occlusion
Papilledema
Retinal hemorrhage
Mucocutaneous
Epistaxis
Gingival bleeding
Cutaneous bleeding
Gastrointestinal bleeding
Other
Shortness of breath
Congestive heart failure
Priapism

the central nervous system (CNS) and eyes predominate (Table 5).^{99,102} Common symptoms include blurred vision, headache, vertigo, dizziness, hearing loss, and impaired mental status. Shortness of breath, chest pain from myocardial ischemia, peripheral arterial occlusion, and venous thromboembolism have been reported. The physical examination often reveals retinal venous engorgement (sausaging), retinal hemorrhages, papilledema, and retinal vein occlusion at later stages (Figure 1). The patient can also have development of localized serous detachments of the fovea, which are thought to be secondary to accumulations of the immunoglobulin and resolve with plasmapheresis. Bleeding complications can be seen, especially purpura and petechiae due to hemostatic defects.

The diagnosis of hyperviscosity requires a high index of suspicion. Most patients have a known diagnosis of a dysproteinemic disorder, but some may present with hyperviscosity as the initial manifestation. The blood smear may reveal rouleaux formation of the red blood cells, in which they stack up like coins (Figure 2). Measurements of serum viscosity may be difficult or impossible to perform in many hospitals, especially if urgently requested outside the usual office hours.

Measurements of immunoglobulin levels will likely be more available in real time and can guide therapy. In patients with typical symptoms and clinical findings, especially those with a known dysproteinemic disorder, treatment can start urgently without laboratory confirmation of hyperviscosity.

Treatment. Therapy should be started without delay in symptomatic patients. Severely symptomatic patients with a known WM diagnosis can be treated with phlebotomy and normal saline replacement while arranging for emergent plasmapheresis. Red blood cell transfusions should be avoided before initiating therapy to prevent exacerbation of the hyperviscosity. Plasmapheresis is an effective method to lower serum viscosity, especially in patients with WM because 80% of the IgM monoclonal protein is intravascular.^{99,105} Even a small reduction in the monoclonal protein concentration can have a major effect on the symptoms. Plasmapheresis does not affect the underlying disease process, and systemic therapy is always needed for durable control of the disease.

Hyperleukocytosis and Leukostasis

Hyperleukocytosis is often defined as a total leukocyte count of $100 \times 10^9/L$ or more, but symptoms of leukostasis can occur at lower leukocyte counts.¹⁰⁶ Hyperleukocytosis can cause microvascular obstruction leading



FIGURE 1. Retinal photograph of a patient with hyperviscosity showing dilated and tortuous retinal veins, intraretinal hemorrhages, and a cotton wool spot (infarction) by the optic disc. Image courtesy of Dr Jose Pulido, Department of Ophthalmology, Mayo Clinic.




FIGURE 2. Red blood cell rouleaux formation in a patient with Waldenström macroglobulinemia (peripheral blood, Wright-Giemsa, original magnification $\times 600$). Image courtesy of Dr Phuong Nguyen, Department of Laboratory Medicine and Pathology, Mayo Clinic.

to tissue hypoxia and infarction (leukostasis). Hyperleukocytosis and leukostasis are most commonly seen in acute leukemias, especially acute myeloid leukemia (AML) (5%-20% of patients).¹⁰⁷⁻¹⁰⁹ Hyperleukocytosis secondary to AML is more common in children than adults. Acute lymphoblastic leukemia is less likely to cause leukostasis than AML. Chronic lymphocytic leukemia and chronic myeloid leukemia rarely cause symptomatic leukostasis, even despite extreme elevations in the white blood cell counts. Symptomatic hyperviscosity can also occur in patients with severe erythrocytosis and thrombocytosis.¹¹⁰

Pathophysiology. Rapid proliferation and disrupted cell adhesion result in the release of a large number of leukemic blasts from the bone marrow into the circulation.¹⁰⁷ This process can lead to microvascular occlusion resulting in tissue ischemia and infarction.¹¹¹ In addition, patients with hyperleukocytosis are at risk for development of TLS and disseminated intravascular coagulation. Two main mechanisms are thought to explain leukostasis.¹⁰⁷ First, the sheer quantity of immature leukocytes (Figure 3), which are frequently larger and less deformable than mature leukocytes, can lead to microvascular occlusion. Frequently, there is no clear correlation between the leukocyte count and the occurrence of leukostasis, likely due in part to a second important mechanism of abnormal interaction between the leukemic blasts and the endothelium. This abnormal interaction may be secondary to aberrant expression of adhesion molecules by the blasts.^{106,112}

Clinical Presentation and Diagnosis. The symptoms and signs of leukostasis can resemble the presentation of hyperviscosity secondary to dysproteinemia (Table 6). Symptoms from the respiratory system and CNS including the eyes are common but can be difficult to distinguish from infectious and hemorrhagic complications.¹⁰⁹ Patients may present with fever, dyspnea, and pulmonary




FIGURE 3. Photomicrographs showing hyperleukocytosis in a patient with chronic myeloid leukemia (A) and a blood smear from a normal individual (B) as a comparison (both peripheral blood, Wright-Giemsa, original magnification $\times 400$). Images courtesy of Dr Phuong Nguyen, Department of Laboratory Medicine and Pathology, Mayo Clinic.

TABLE 6. Clinical Manifestations of Leukostasis

Central nervous system
Headache
Dizziness and vertigo
Seizures
Confusion and delirium
Impaired level of consciousness and coma
Focal neurologic deficits
Intracranial hemorrhage
Ophthalmologic
Blurry vision or loss of vision
Visual field defect
Papilledema
Retinal hemorrhage
Retinal vein thrombosis
Pulmonary
Dyspnea and tachypnea
Hypoxia
Auscultatory crackles
Respiratory failure
Pulmonary infiltrates
Cardiovascular
Chest pain
Myocardial ischemia/infarction
Other
Fever
Renal failure
Priapism
Extremity ischemia
Venous thrombosis
Disseminated intravascular coagulation
Tumor lysis syndrome

infiltrates resembling symptoms of pneumonia or volume overload. Fever with neurologic symptoms can be difficult to distinguish from CNS infections. There is no single diagnostic test for leukostasis, but the diagnosis should be considered in all patients with extreme leukocytosis and typical symptoms.

Treatment. Hyperleukocytosis and leukostasis in patients with acute leukemia are associated with an inferior prognosis with an increase in early deaths compared with patients without these complications, and therapy should be started without unnecessary delay.^{107,113} Red blood cell transfusions should be administered with caution and preferably after control of the symptoms of leukostasis given the concern of increasing viscosity.¹¹⁴ Leukapheresis, a mechanical separation and removal of leukocytes from the blood, can rapidly reduce the number of

leukemic blasts and reduce the likelihood of complications, but the effect of leukapheresis on early mortality is uncertain.¹¹⁵⁻¹¹⁷ Despite the uncertainties, it should be strongly considered for all patients presenting with symptomatic leukostasis. The goal of leukapheresis should be resolution of symptoms, typically with reduction of the blast count to less than $100 \times 10^9/L$ in AML.^{106,118,119}

Hydroxyurea is commonly used to provide additional control by preventing rapid reaccumulation of blasts in the initial stages of therapy, again with an uncertain effect on mortality in isolation.¹¹⁵ Rapid initiation of standard induction therapy with curative intent is therefore recommended in all patients in whom intensive therapy is appropriate. Hydroxyurea can be considered as a bridging strategy while awaiting the results of diagnostic tests. Cranial radiation is no longer routinely recommended. Patients with leukostasis are at greater risk for TLS and should receive prophylactic therapy.

NEUROLOGIC EMERGENCIES

Malignant Spinal Cord Compression

Malignant spinal cord compression (MSCC) is a true oncological emergency. Up to 6% of patients with cancer are expected to experience MSCC at some time during the course of their illness, and the annual incidence of hospitalizations secondary to MSCC among patients with advanced cancer is 3.4%.¹²⁰⁻¹²² All cancers can cause MSCC, but the most often implicated malignant diseases are breast, lung, and prostate cancer, which account for almost two-thirds of all cases, but multiple myeloma and non-Hodgkin lymphoma have the highest cancer-specific incidence.¹²¹⁻¹²³ The prognosis of patients with MSCC is poor, especially if the presenting features include paralysis or if there is no response to therapy.^{121,124} Slower onset of symptoms and the absence of neurologic deficits at diagnosis predict a better functional outcome after therapy.^{125,126}

Pathophysiology. Most cases of MSCC are secondary to metastases to vertebral bodies that erode into the spinal canal and encroach on the spinal cord. Paravertebral tumors can extend through the neural foramina, resulting

in cord compression.¹²⁷ Intramedullary and meningeal metastases are rare causes of spinal cord compression.^{128,129} The thoracic spine is the most common location for metastases, followed by the lumbar spine and cervical spine.^{120,128,130} Injury to the spinal cord can occur secondary to direct compression of the cord or from cord ischemia from vascular occlusion secondary to the tumor. Both mechanisms will eventually lead to irreversible neuronal damage resulting in neurologic deficits if untreated.

Clinical Presentation and Diagnosis. The literature on the natural history and early identification of MSCC is limited, but known bone metastases, high tumor burden, and recent onset of symptoms are suggestive of MSCC in patients with cancer who have back pain.¹³¹ Most patients have back pain at diagnosis, but in 5% to 15% the pain is either absent or mild.^{120,130,132-134} The pain can be localized to the spine, radicular, or both and is usually progressive.¹³⁰ The back pain is often nocturnal and can be worsened by certain movements as well as with increase in intra-abdominal pressure such as the Valsalva maneuver. Guidelines for evaluation of back pain have recommended looking for “red flags” suggestive of malignant disease, but there is limited evidence that such red flags are useful in identifying cancer as the underlying source of back pain.^{135,136} Twenty percent of patients do not have a known cancer diagnosis at the time the MSCC is diagnosed.^{133,134,137} Back pain in patients with cancer, especially pain of recent onset and worsening pain, should be taken very seriously and considered to be secondary to MSCC until proven otherwise. A careful history and a thorough physical examination including a neurologic examination are critical when evaluating back pain in patients with cancer. Weakness is the second most common presenting feature of MSCC, and patients may report heaviness or clumsiness of an extremity, which on examination is secondary to motor weakness. Up to 70% of patients are unable to walk at the time of presentation.^{120,127,132} Sensory deficits usually occur after motor deficits, and up to 70% of patients will have sensory deficits at diagnosis.¹²⁷ Autonomic symptoms such as loss of bladder and bowel function

usually occur later in the course of MSCC.^{120,130} Ataxia is an unusual manifestation of MSCC.¹³⁸ Other presenting symptoms of MSCC include radicular pain and gait disturbance.^{120,127,130,132}

The diagnostic method of choice is magnetic resonance imaging (MRI) because it is both sensitive and specific (Figure 4).¹³⁹⁻¹⁴³ It is important to image the entire spine because up to 40% of patients may have multiple levels of compression or cord impingement.¹⁴⁴⁻¹⁴⁷ If imaging of the entire spine is not feasible on initial evaluation, focused MRI of the suspected area should be performed emergently with a more complete MRI evaluation of the entire spine as soon as possible.¹⁴² Computed tomography (CT), with or without myelography, can be used when MRI is contraindicated or not available. Plain bone radiographs and radionuclide bone scans are insensitive for spinal cord compression. Positron emission tomography with CT imaging is a useful modality to identify metastasis to the spine but lacks anatomic detail for diagnosis of MSCC.¹⁴⁸

Treatment. Therapy should be initiated without delay in all patients with suspected MSCC to help preserve neurologic function, preferentially after imaging studies have been performed. Pretreatment motor function is an important predictor of functional outcome after therapy for MSCC.^{124,125,149,150} If there is a delay in obtaining imaging studies, corticosteroid therapy may be initiated without confirmation of the diagnosis. Dexamethasone is the most commonly used glucocorticoid. A typical initial dose is 10 to 16 mg IV followed by 4 mg every 4 to 6 hours. The use of higher doses of dexamethasone (up to 100 mg) may result in a slightly better neurologic outcome but is associated with a higher risk of adverse events and is not universally supported in the literature.¹⁵¹⁻¹⁵⁵ High-dose dexamethasone can be considered in patients with severe and progressive neurologic deficits in whom the small potential gain may outweigh the risks.

Almost all patients with MSCC should be evaluated urgently for a decompressive surgical procedure. A randomized clinical trial evaluated surgical intervention in addition to high-dose dexamethasone and radiation therapy.¹⁵⁶ The trial was stopped early




FIGURE 4. Metastatic spinal cord compression. Sagittal (A) and cross-sectional (B) views show metastasis to the thoracic spine in a patient with lung cancer resulting in symptomatic cord compression.

because the predetermined criteria were met, with surgical patients more likely to be able to walk after therapy compared with those who received radiation and dexamethasone alone (84% vs 57%; $P=.003$). Furthermore, patients in the surgical group remained ambulatory for a longer period (122 days vs 13 days) and had better survival. An unplanned subgroup analysis suggested that the benefit was related to age, with younger patients being more likely to benefit.¹⁵⁷ Other researchers have questioned the generalizability of the results of the trial to a broader cohort of patients because the study patients were highly selected. Moreover, the outcome in the nonsurgical group was inferior to that found in other studies. A matched pair analysis comparing patients who underwent surgical intervention plus radiotherapy with patients receiving radiotherapy alone did not show a benefit from surgical intervention.¹⁵⁸ Until more data become available, it is appropriate to have most patients evaluated for a decompressive surgical procedure, especially younger patients and those with better performance status, evidence of spinal instability, or rapidly progressive symptoms. A scoring system has been proposed to predict the prognosis of patients with MSCC, and those in the poorest prognosis group may best be served with corticosteroids, short-course radiation therapy, and best supportive care.¹⁵⁹

Radiation therapy remains the mainstay of the treatment for most patients with MSCC, whether they do or do not undergo a decompressive surgical procedure. Multiple radiation regimens are in use, but none has emerged as the standard.^{155,160,161} Shorter courses of radiation therapy may be as effective as longer courses, especially for patients with poor prognosis.¹⁶²⁻¹⁶⁴ Stereotactic radiosurgical procedures may be considered in selected cases, especially after resection.¹⁶⁵⁻¹⁶⁷

Brain Metastases

Brain metastases are a common complication in cancer, occurring in up to 20% of patients.¹⁶⁸ The incidence of symptomatic brain metastases is not well known, but autopsy studies have found that the prevalence of brain metastases is higher than clinically appreciated antemortem.^{169,170} The cancers most likely to metastasize to the brain are lung cancer (both non—small cell and small cell), breast cancer, renal cell cancer, and malignant melanoma.^{171,172} About 50% of brain metastases are solitary.¹⁷¹

Pathophysiology. Brain metastases arise secondary to hematogenous dissemination of tumor cells to the brain. The biology of brain metastases is complex.¹⁷³ The distribution within the brain reflects the distribution of blood flow, with 80% of brain metastases




FIGURE 5. Contrast-enhanced T2-weighted magnetic resonance image showing symptomatic cerebellar metastasis with associated cerebellar edema and distortion of the fourth ventricle in a patient with esophageal adenocarcinoma.

occurring in the cerebral hemispheres,¹⁶⁹ 15% in the cerebellum, and 3% in the brain stem. Brain metastases are frequently located in the watershed areas of the arterial circulation and at the junction of gray and white matter.¹⁷⁴ Brain metastases frequently result in cerebral edema and subsequently elevated intracranial pressure. The etiology of the edema is complex and includes vasogenic edema secondary to leaky capillaries, stasis from impaired venous drainage, and obstruction of cerebrospinal fluid by the tumor.¹⁷⁵

Clinical Presentation and Diagnosis. Most patients presenting with brain metastases have a known diagnosis of cancer, and the highest incidence is in patients with advanced malignant disease.¹⁷⁶ Brain metastases can also be the first presentation of a malignant disorder. The presenting features of brain metastases are variable, but headache is the most common symptom.^{174,177} Other symptoms depend on the location of the lesion within the brain. Common symptoms include motor and sensory deficits, speech disturbance, unsteadiness, and cognitive decline. Up to 10% of patients have seizures, usually when there are multiple brain metastases.¹⁷⁴ A hemorrhage

into a brain metastasis can result in sudden and severe symptoms.

Contrast-enhanced MRI is the most sensitive imaging modality for brain metastases (Figure 5).^{178,179} Contrast-enhanced CT can be used when MRI is either unavailable or contraindicated but is less sensitive for smaller tumors and posterior fossa tumors. Noncontrast CT is helpful when an intracranial hemorrhage is suspected.

Treatment. The prognosis of most patients with brain metastases is poor, and other factors in addition to the presence of brain metastases determine the prognosis. Those factors include the tumor type, age at diagnosis, the performance score, and the presence of extracranial disease. Several scoring systems have been proposed, and one useful and accurate system is the Graded Prognostic Assessment, which is easily applied in clinical practice.¹⁸⁰ Patients with poor performance may be best served with supportive care alone. Table 7 lists treatment options for intracranial hypertension and seizures. Glucocorticoids are indicated in all symptomatic patients with cerebral edema secondary to metastases, and the effect of therapy occurs within several hours.¹⁷⁵ A commonly used glucocorticoid is dexamethasone, but others are likely as effective as long as they are given in equipotent doses.¹⁸¹ Dexamethasone is generally preferred because it has a long half-life and less mineralocorticoid activity.¹⁸¹ The optimal dose is unknown, but one trial reported no benefit of higher doses of dexamethasone (16 mg/d) vs lower doses (4-8 mg/d) in patients with no signs of impending brain herniation.¹⁸² Therefore, a reasonable starting dose is 4 to 8 mg/d unless the patient has severe symptoms, in which case 16 mg/d can be considered.¹⁸³ Dexamethasone has excellent oral bioavailability and can therefore be given orally in patients with intact mentation and a functioning gastrointestinal tract. The dexamethasone should be tapered over 3 to 4 weeks after more definitive therapy. Patients with asymptomatic brain metastases and minimal edema do not need glucocorticoids. Seizures occur in 10% to 20% of patients and should be treated aggressively.¹⁸⁴ Prophylactic anticonvulsant therapy is not recommended for patients who have not had seizures.¹⁸⁵⁻¹⁸⁸

TABLE 7. Management of Intracranial Hypertension and Seizures

Disorder	Intervention	Dosage and comments
Intracranial hypertension	Dexamethasone	4-8 mg/d in divided doses; a higher dose can be used with severe symptoms (10-16 mg IV followed by 4 mg IV every 6 h)
Seizures	Lorazepam	2-4 mg IV (or 0.1 mg/kg up to 4 mg maximum) at 2 mg/min; total dose capped at 4 mg
	Phenytoin	20 mg/kg IV at 50 mg/min (25 mg/min in elderly patients and patients with cardiovascular disorders)
	Fosphenytoin	20 mg/kg PE at 150 mg/min

IV = intravenous; PE = phenytoin equivalent.

The treatment of refractory seizures in patients with cancer is no different than that in patients without cancer.¹⁸⁹ More definitive therapy for brain metastases, including resection, radiation, and chemotherapy, is offered to patients with good performance status and more favorable prognosis.^{168,190} Surgical resection can rapidly decrease the intracranial pressure, especially in patients with tumors in the posterior fossa. A neurosurgeon should be consulted for all cases in which an operative intervention may be indicated.

CARDIOVASCULAR EMERGENCIES

Malignant Pericardial Effusion and Cardiac Tamponade

Pericardial effusions are commonly seen in patients with advanced and metastatic malignant diseases, but most patients are asymptomatic and do not require urgent therapy. Pericardial effusions in patients with cancer are not always related to the malignant disease itself and may also be secondary to cancer therapy, especially radiotherapy, or a manifestation of either an infection or an autoimmune process.^{191,192}

Pathophysiology. Pericardial effusions in patients with cancer can be secondary to metastases to the pericardium, tumor invasion of the pericardium, or treatment related. Large effusions, especially if they accumulate rapidly, can impair ventricular filling and reduce cardiac output.¹⁹³ Patients with slowly accumulating effusions are frequently asymptomatic despite large effusions.

Clinical Presentation and Diagnosis. Small pericardial effusions are often asymptomatic.

Typical symptoms of large or rapidly accumulating effusions include dyspnea, cough, and chest pain. A physical examination may reveal tachycardia, hypotension, distant heart sounds, fixed jugular venous distention, peripheral edema, and pulsus paradoxus. In addition, patients with tamponade can have hypotension and shock.^{193,194} Electrocardiography frequently reveals low-voltage and nonspecific ST-T changes. Electrical alternans (beat-to-beat variations in the QRS complex size and shape) is thought to be caused by the heart moving within the enlarged and fluid-filled pericardium but can be seen in other cardiac conditions (Figure 6).¹⁹⁵ The diagnosis of pericardial effusions and tamponade is best made by echocardiography, which confirms the presence of the effusion but also provides hemodynamic information (Figure 7).¹⁹⁶ Computed tomography and MRI can also provide valuable information, especially regarding tumor invasion and metastases to the pericardium.¹⁹⁷ Cytological examination of the pericardial fluid may reveal malignant cells, but occasionally a pericardial biopsy is needed to establish the diagnosis.

Treatment. Small and asymptomatic pericardial effusions do not need to be treated. Patients with symptomatic effusions, especially with rapidly developing symptoms and hemodynamic instability, may need urgent interventions. Therapeutic echocardiographically guided pericardiocentesis is a safe procedure that can immediately relieve symptoms and improve hemodynamics, but a more durable treatment is usually needed.¹⁹⁸ A pericardial drain can be placed for drainage, and in selected cases, surgical procedures or instillation of a sclerosing agent may be used.^{199,200}




FIGURE 6. Electrocardiogram showing electrical alternans in a patient with malignant pericardial effusion. Image courtesy of Dr Donald Brown, Division of Cardiology, University of Iowa Hospitals and Clinics.

Systemic chemotherapy and/or radiotherapy may prevent reaccumulation in some patients.¹⁹²

Superior Vena Cava Syndrome

Superior vena cava syndrome (SVCS) occurs in the setting of an extrinsic compression or other occlusion of the superior vena cava (SVC). It is a common complication of cancer, and thoracic malignant disorders are the most common cause of SVCS.^{201,202} Superior vena cava syndrome can also be seen as a complication of benign conditions such as SVC thrombosis secondary to indwelling venous lines or pacemaker leads as well as a complication of fibrosing mediastinitis and histoplasma infection.^{201,203,204}

Pathophysiology. The thin-walled SVC can easily be compressed by tumors outside of the vessel, resulting in impaired venous drainage from the head, neck, and upper extremities. The compressing tumors are frequently in the middle or anterior mediastinum and the right paratracheal and precarinal nodal regions. The compression results in the formation of venous collaterals, including the azygos vein. Superior vena cava syndrome secondary to a

compression below the azygos vein can result in more severe symptoms, highlighting the importance of the azygos vein as a collateral vessel.²⁰⁵

Clinical Presentation and Diagnosis. Superior vena cava syndrome can be acute, subacute, or more insidious and sometimes occurs with minimal symptoms. Very highly proliferative tumors and SVC thrombosis can result in a rapid onset of symptoms. Common symptoms include dyspnea, orthopnea, cough, sensation of fullness in the head and face, and headache, often exacerbated by stooping. Less common symptoms are chest pain, hemoptysis, hoarseness, dizziness, light-headedness, and even syncope. The most common physical findings are facial and neck swelling, arm swelling, and dilated veins in the chest (Figure 8, A), neck, and proximal part of the arms. Stridor and mental status changes are worrisome signs and indicate laryngeal edema and increased intracranial pressure, respectively. A grading system for SVCS has been proposed that can easily be applied in clinical practice (Table 8).²⁰⁶ Computed tomography with IV contrast is the most useful method of diagnosing SVCS (Figure 8, B).^{202,207} A plain chest




FIGURE 7. Transthoracic echocardiographic subcostal 4-chamber view showing a large circumferential pericardial effusion. Image courtesy of Dr S. Allen Luis, Division of Cardiovascular Diseases, Mayo Clinic.

radiograph may suggest SVCS, usually by showing a right hilar mass. Magnetic resonance imaging is particularly helpful in cases in which the administration of IV contrast is contraindicated.

Treatment. Although SVCS is commonly considered an oncological emergency, most cases are not.^{206,208,209} Patients with symptoms and signs concerning for cerebral and/or airway edema and circulatory instability need urgent initiation of therapy (Table 8). In cases in which the etiology is not yet known, there is usually time to establish a diagnosis before starting therapy. Endovascular stenting of the SVC can promptly relieve symptoms of SVCS and is the treatment of choice in very symptomatic patients (Figure 9).^{210,211} Radiation therapy is effective for many patients, but the relief of symptoms may be slow.

Tissue diagnosis should be established before initiating radiation therapy. Adjunctive supportive therapy may be useful, such as elevation of the head of the bed, supplemental oxygen, and cautious use of diuretics and glucocorticoids in cases of laryngeal edema. Glucocorticoids administered for SVCS secondary to lymphoma relieve symptoms but should typically not be given until the diagnosis has been established with a biopsy because corticosteroids may obscure the pathologic diagnosis. Corticosteroids have little or no role in SVCS secondary to lung cancer.²¹² Anticoagulation should be reserved for patients with evidence of an SVC thrombus or other venous thromboembolic complications and considered for patients who undergo a stent placement. Catheter-directed thrombolysis can be useful in SVCS secondary to a thrombus.²¹³ More definitive therapy, such as systemic therapy and radiation therapy, is dictated by the underlying cancer, which also is the primary determinant of the patient's prognosis.

PULMONARY EMERGENCIES

Acute Airway Obstruction

Malignant thoracic and mediastinal tumors can erode into the major airways or cause extrinsic compression leading to airway obstruction. The most common cause of cancer-related airway obstruction is lung cancer, and up to one-third of patients may experience airway obstruction during the course of the illness.²¹⁴ Other cancers, including anaplastic thyroid cancer,




FIGURE 8. Superior vena cava syndrome in a patient with a large malignant mediastinal mass. A, Extensive venous collaterals can be seen on the right side of the chest wall and the right arm. B, Computed tomogram shows dilated superficial veins in the anterior chest wall.

TABLE 8. Grading of Superior Vena Cava Syndrome

Grade	Category	Definition	Urgent treatment needed
0	Asymptomatic	Radiographic superior vena cava obstruction in the absence of symptoms	No
1	Mild	Edema of the head or neck (vascular distention), cyanosis, plethora	No
2	Moderate	Facial and neck edema with functional impairment (mild dysphagia, cough, mild or moderate impairment of head, jaw, or eyelid movements, visual disturbances caused by ocular edema)	No
3	Severe	Mild or moderate cerebral edema (headache, dizziness) or mild/moderate laryngeal edema or diminished cardiac reserve (syncope after bending)	Yes
4	Life-threatening	Severe cerebral edema (confusion, obtundation), laryngeal edema (stridor), or hemodynamic compromise (syncope without precipitating factors, hypotension, renal insufficiency)	Yes
5	Fatal	Death	Not applicable

Adapted from *J Thorac Oncol*,²⁰⁶ with permission from the International Association for the Study of Lung Cancer.

squamous cell cancers of the head and neck, and mediastinal malignant diseases such as lymphoma and germ cell tumor, can also cause airway obstruction. Primary tracheal tumors are a rare cause of airway obstruction.

Clinical Presentation and Diagnosis. The most common symptoms include dyspnea, cough, wheezing, hemoptysis, and stridor, and the manifestations depend on the severity and location of the obstruction.^{215,216} The symptoms of airway obstruction can resemble symptoms of worsening chronic obstructive pulmonary disease, which is a common comorbidity in patients with lung cancer. The physical examination frequently reveals focal wheezing on auscultation and inspiratory stridor. Computed tomography is the preferred method of evaluation and provides information on the extent of the cancer as well as the airway involvement. The obstruction can be visualized with bronchoscopy, and biopsies can be performed at the same time if needed.

Treatment. The treatment of airway obstruction requires good visualization of the larger airways, which usually necessitates the use of rigid bronchoscopy.²¹⁶ The goal of therapy is to restore airway patency, which can be achieved with a variety of modalities.²¹⁷ Supplemental oxygen should be given to patients awaiting interventions, and bronchodilator therapy may be indicated in patients with coexisting obstructive small airways disease.

Airway stenting, laser therapy, argon plasma coagulation, photodynamic therapy, and brachytherapy have all been used in the management of central airway obstruction and result in substantial relief of symptoms in most patients.^{218,219} Interventions such as stent placement can have severe negative consequences such as subsequent airway infections.^{220,221} External beam radiation therapy and systemic chemotherapy play an important role in the subsequent management of malignant airway occlusion.

Acute Airway Hemorrhage

The etiologies of hemoptysis are diverse and vary with anatomic location. Malignant disease is among the most common causes of hemoptysis. Tumors eroding into the airways can cause hemoptysis, which usually is not an emergency. Substantial airway hemorrhage leads to hypoxemia and can be fatal.^{222,223} The definition of massive hemoptysis is not well established, and definitions of 100 to 600 mL of bloody expectoration over 24 hours have been used.²²⁴ Airway hemorrhage is commonly divided into proximal and distal airway bleeding, and the causes and management differ according to the anatomic location.²²⁵ Lung cancer is the most common cause of massive hemoptysis, but other cancers, especially squamous cell carcinoma of the head and neck, can bleed profusely into the airways.

Clinical Presentation and Diagnosis. Patients usually present with expectoration of bloody



FIGURE 9. Insertion of a stent in the SVC can promptly improve the symptoms of superior vena cava syndrome. Images courtesy of Dr Haraldur Bjarnason, Department of Radiology, Mayo Clinic.

mucus or frank blood. Other symptoms and signs include dyspnea, respiratory distress, hypoxia, and hemodynamic instability. It is important to promptly identify the source of bleeding in patients with hemoptysis who are considered for more aggressive therapy. Computed tomography, especially CT angiography, can provide important information regarding the location of the bleeding and may help select an appropriate treatment strategy.^{226,227} Bronchial artery angiography frequently reveals the bleeding location, and therapeutic embolization can be performed at the same time.

Treatment. As with acute airway obstruction, securing the airway is of utmost importance. The patient should be positioned in the lateral decubitus position with the bleeding side down, if known, to preserve alveolar exchange

in the unaffected lung. If the patient is intubated, the bronchial main stem of the affected side can also be selectively intubated to avoid bleeding into the unaffected side. Administration of IV fluids and blood products may be needed for stabilization, especially in patients with hemodynamic instability or thrombocytopenia. Coagulation abnormalities should be corrected as indicated with blood products and reversal of anticoagulants if needed. Recombinant factor VII has been used to treat massive hemoptysis in patients with cancer and can be considered when other measures fail.^{228,229} Rigid bronchoscopy is the preferred method for control of airway hemorrhage, but other treatments are frequently needed.²²⁵ Bronchial artery angiography can identify the bleeding vessel(s), and embolization can be performed during the procedure, often with successful control of the bleeding.²³⁰⁻²³²

Massive hemoptysis is extremely distressing to both patients and their caregivers and is often a terminal event in the disease course. Best supportive care without further interventions may be appropriate in selected cases. Intravenous administration of opioids and benzodiazepines may provide substantial relief but with the risk of suppressing respiratory drive. Darkly colored bed sheets, pillowcases, and towels may decrease the psychological trauma associated with massive hemoptysis.

INFECTIOUS EMERGENCIES

Febrile Neutropenia

Infections are common in patients with cancer and a major contribution to both morbidity and mortality. Most infections in patients with cancer are not emergencies and can be treated in the outpatient setting. Febrile neutropenia is a common complication in patients undergoing therapy for malignant disease. Prompt diagnosis and initiation of therapy are of key importance in decreasing morbidity and mortality and can also decrease costly hospitalizations. For the purpose of this review, we use the definitions of the Infectious Diseases Society of America. Fever is defined as a single oral temperature higher than 38.3°C or a temperature higher than 38.0°C sustained for more than 1 hour.²³³ Neutropenia is defined as an absolute neutrophil count (ANC) of less than $0.5 \times 10^9/L$ or an ANC that is expected to decrease to less than $0.5 \times 10^9/L$ during the next 48 hours.^{233,234} An ANC level of less than $0.1 \times 10^9/L$ is defined as profound neutropenia.²³³

Pathophysiology. Febrile neutropenia is most common in patients receiving cytotoxic chemotherapy, especially patients with acute leukemia. Febrile neutropenia is much less common in patients undergoing therapy for solid tumors given the less intensive therapy. Some malignant disorders, especially sarcomas and germ cell tumors, require high-intensity chemotherapy, which increases the risk of febrile neutropenia (Table 9).²³⁵ The risk of febrile neutropenia depends on both the severity and duration of neutropenia. The neutrophil nadir usually occurs 5 to 10 days from initiation of therapy, and neutrophil recovery begins about 5 days later, but there are

substantial variations depending on the regimens used and the patient characteristics. Preexisting comorbidities such as liver or kidney dysfunction as well as concurrent use of certain drugs can increase the severity and duration of the neutropenia (Table 9). Patients with bone marrow dysfunction, especially acute leukemia, myelodysplastic syndromes, and aplastic anemia, as well as drug- or radiation-induced neutropenia can present with febrile neutropenia in the absence of cytotoxic chemotherapy. Factors other than the neutropenia itself play a role in the pathogenesis of febrile neutropenia. Chemotherapy can disrupt mucosal barriers, making the risk of gram-negative sepsis greater. Indwelling vascular devices can serve as the port of entry for organisms that colonize the skin such as gram-positive cocci. Hematologic cancers are often associated with defects in both humoral and cellular immunity, further adding to the immunosuppressive effects of the cancer-directed therapy.

Microbiology. Most patients with febrile neutropenia will not have a specific microbial pathogen isolated during their illness, and a focus of an infection may not be identified. A bacterial pathogen is isolated in less than 30% of patients during an episode of febrile neutropenia and is more common in patients with prolonged or profound neutropenia.²³³ The epidemiology of bacterial infections during neutropenia has changed markedly in recent decades. Gram-negative bacteria were the most commonly identified cause of febrile neutropenia in the past, but more recently, the incidence of gram-positive infections has surpassed those caused by gram-negative bacteria.^{236,237} In recent years, an increase in the incidence of gram-negative bacteria has been observed, but infections with gram-positive bacteria are still in the majority.^{238,239} The most common gram-positive bacteria are coagulase-negative staphylococci. Among the gram-negative bacteria, *Escherichia coli*, *Klebsiella*, and *Pseudomonas aeruginosa* are the most commonly isolated. Fungal and viral infections are also frequently encountered. The risk of fungal infections increases with the duration and severity of the neutropenia and is a common etiology of persistent neutropenic fever in patients treated empirically with

TABLE 9. Risk Factors for Febrile Neutropenic Episodes

Risk factors	Effect on risk	Reported febrile neutropenia rate
Patient characteristics		
Advanced age	Increased risk if age ≥ 65 y	NA
ECOG performance status	Increased risk if ≥ 2	NA
Nutritional status	Increased risk if albumin < 35 g/L (3.5 g/dL)	NA
Prior febrile neutropenia	Increased risk if FN during the first cycle	NA
Comorbidities	FN odds increase by 27%, 67%, and 125%, respectively, for 1, 2, or 3 comorbidities	NA
Underlying malignant disorder		
Acute leukemia/MDS	NA	85%-95%
Soft tissue sarcoma	NA	27%
NHL/myeloma	NA	26%
Germ cell tumors	NA	23%
Hodgkin lymphoma	NA	15%
Ovarian carcinoma	NA	12%
Lung cancer	NA	10%
Colorectal cancer	NA	5%
Breast cancer	NA	5%
Prostate cancer	NA	1%
Cancer stage	Increased risk if stage II or higher	NA
Remission status	Increased risk if not in remission	NA
Treatment response	Increased risk in patients not responding to therapy	NA
Treatment characteristics		
Cytotoxic regimen	Increased risk with higher doses of chemotherapy	NA
Degree and duration of mucositis	Higher risk with more severe mucositis	NA
Neutropenia	Absolute neutrophil count $< 0.5 \times 10^9/L$ for ≥ 7 d	NA
Lymphopenia	Absolute lymphocyte count $< 0.7 \times 10^9/L$	NA
Monocytopenia	Absolute monocyte count $< 0.15 \times 10^9/L$	NA
Prophylactic use of growth factors	Reduces the risk in selected populations	NA

ECOG = Eastern Cooperative Oncology Group; FN = febrile neutropenia; MDS = myelodysplastic syndrome; NA = not available; NHL = non-Hodgkin lymphoma. Adapted from Flowers CR et al. *J Clin Oncol*. 2013;31(6):794-810.²³⁵ Reprinted with permission. ©2013 American Society of Clinical Oncology. All rights reserved.

broad-spectrum antibiotics. A more detailed review of the microbiology of febrile neutropenia is outside the scope of this review, but it is important to understand that there are substantial geographic variations, both in the type of pathogens implicated and in their resistance patterns regarding antimicrobial therapy.

Clinical Presentation and Diagnosis. The predominant sign at diagnosis is fever, but patients may also present with localizing symptoms and signs. A thorough history and physical examination are essential in the initial evaluation of patients with febrile neutropenia, even though a focus of infection is frequently not found. Emphasis should be placed on the oral cavity and oropharynx, skin, lungs, abdomen, and perianal area. Because of the lack of neutrophils, clinical and laboratory findings may be atypical. Purulence and swelling are frequently absent, and the only sign of a

soft tissue infection may be erythema. The oral cavity should be examined for the presence of mucosal ulcers and periodontal disease. The skin should be carefully evaluated. All sites of indwelling venous devices should be thoroughly examined for erythema and tenderness. For example, port sites and line exit sites should be gently palpated and all dressings removed if needed for better visualization. Abdominal examination may reveal tenderness suggestive of enterocolitis, and examination of the lungs can identify focal abnormalities or tachypnea. The perianal region should be examined for erythema and tenderness, but a digital rectal examination should be avoided. Central nervous system infections may present with nonspecific symptoms of confusion or subtle focal findings. Patients should undergo risk assessment at presentation, as factors such as advanced age, poor performance status, and comorbidities may increase the risk of serious complications.

A complete blood count with differential, liver chemistry tests, electrolyte panels, lactic acid measurements, coagulation tests, and creatinine measurements should be performed at presentation. At least 2 sets of blood specimens should be collected for cultures, with one from a peripheral vein. If the patient has an indwelling venous access device, specimens for culture should be obtained from each lumen in addition to a culture specimen from a peripheral vein. Other samples should be collected as clinically indicated, such as urine and stool samples. Very neutropenic patients may not have pyuria, pulmonary infiltrates, or cerebrospinal fluid leukocytosis. Samples should be obtained from skin lesions and sent for cultures, fungal stains, and virologic examination as indicated. Discharge from any line exit sites should be submitted for bacterial cultures. A lumbar puncture should be performed in patients with suspected meningitis, but platelet transfusion should be administered to patients with a platelet count of less than $50 \times 10^9/L$ before the procedure. Chest radiography should be done in all patients with respiratory signs and symptoms, and CT imaging should be considered in patients with high risk of complications. Given its greater sensitivity, high-resolution CT should be performed in patients with suspected respiratory infection but no abnormalities on chest radiography.²⁴⁰ The role of circulating blood markers such as C-reactive protein and procalcitonin is unclear. Procalcitonin may have a role when used with other predictors in risk stratification of patients with febrile neutropenia.^{241,242}

Treatment. Early recognition and treatment of febrile neutropenia are key to successful management (Figure 10). Not all patients with neutropenic fever need to be admitted to the hospital. Empirical antibiotic therapy should be initiated without delay once samples for microbial cultures have been obtained. Delays in the initiation of antimicrobial therapy have been associated with inferior outcomes in patients admitted to the hospital with sepsis.^{243,244} A systemic and algorithmic method to identify patients with febrile neutropenia and start appropriate therapy has been found to reduce the time from triage to initiation of antibiotics.^{245,246}

Patients with low risk can be considered for outpatient IV or possibly oral antibiotic therapy assuming they meet certain criteria.^{234,235,247} A useful risk stratification tool is the Multinational Association for Supportive Care in Cancer risk index score (Table 10).²⁴⁸ Other risk stratification models exist, such as the National Comprehensive Cancer Network guidelines for management of cancer-related infections²⁴⁹ and the Clinical Index of Stable Febrile Neutropenia.²⁵⁰ Patients with anticipated longer duration and greater severity of neutropenia (>7 days, ANC $<0.5 \times 10^9/L$) as well as patients with major comorbidities are considered to be at high risk and should be hospitalized for therapy. Other indications for an admission include the presence of renal or hepatic insufficiency, hypotension, severe mucositis, pneumonia, hypoxia, new-onset abdominal pain, neurologic changes including mental status abnormalities, and suspected line infections. Patients with afebrile neutropenia who have new or worsening signs and symptoms of an infection should be evaluated and treated as being at high risk and be admitted to the hospital. For outpatient antibiotic therapy to be successful, the patient must have prompt access to health care professionals for evaluation as needed; have reliable transportation and access to a telephone; and have a reliable caregiver who is with them all the time. If there are any doubts regarding the safety of outpatient therapy, the patient should be hospitalized. A recommended outpatient oral regimen is a combination of amoxicillin/clavulanic acid and ciprofloxacin, but this regimen will depend on many factors including clinical presentation, absence of comorbidities, access to rapid advanced health care, antimicrobial prophylaxis, and resistance patterns.^{251,252} Patients previously taking a prophylactic fluoroquinolone antibiotic should not receive fluoroquinolone-based empirical antibiotic therapy.²³⁴ Low-risk patients with hematologic cancers can be treated as outpatients with IV chemotherapy, often in a hospital-based outpatient environment.

Monotherapy with a broad-spectrum cephalosporin such as cefepime, a carbapenem, or an antipseudomonal β -lactam such as piperacillin/tazobactam is recommended as initial therapy by the Infectious Diseases




FIGURE 10. Algorithm for initial management of febrile neutropenia. ANC = absolute neutrophil count; MASCC = Multinational Association for Supportive Care in Cancer.

Society of America.²³³ Gram-positive coverage should be considered in selected patients and not employed routinely for all patients. Patients with hypotension, sepsis, or suspected catheter-related infection should receive an antibiotic with adequate gram-positive activity such as vancomycin. Table 11 lists other indications for gram-positive coverage. Knowledge of the susceptibility patterns in the community and within institutions and hospitals is important when selecting the appropriate initial therapy. Empirical antifungal or antiviral therapy is not routinely recommended unless

there is a high risk for or suspicion of a fungal or viral infection. The role of myeloid growth factors is uncertain. They may reduce the duration of hospital stay but do not seem to improve mortality.²⁵³ Myeloid growth factors can be considered in patients with neutropenic fever who are at risk of severe complications. Such patients include those with expected prolonged (>10 days) and profound neutropenia, pneumonia, hypotension, uncontrolled primary cancer and multiorgan dysfunction, or sepsis and those who are older than 65 years.²⁵⁴

TABLE 10. MASCC Scoring System for Patients With Neutropenic Fever^{a,b}

Characteristic	Score
Burden of febrile neutropenia: no or mild symptoms ^c	5
No hypotension	5
No chronic obstructive pulmonary disease	4
Solid tumor or no previous fungal infection	4
No dehydration	3
Burden of illness: moderate symptoms	3
Outpatient status	3
Age <60 y	2

^aMASCC = Multinational Association for Supportive Care in Cancer.

^bPatients with a total score of ≥ 21 have a low risk of having serious medical complications.

^cBurden of neutropenia reflects the clinical status of the patient and is scored on the following scale: no or mild symptoms, score of 5; moderate symptoms, score of 3; severe symptoms or moribund, score of 0. Points attributed to the variable "burden of febrile neutropenia" are not cumulative. Therefore, the maximum theoretical score is 26.

Adapted from Klastersky J et al. *J Clin Oncol*. 2000;18(16):3038-3051.²⁴⁸ Reprinted with permission. Copyright ©2017 American Society of Clinical Oncology. All rights reserved.

Fever in Patients Without a Functional Spleen

Patients who have either undergone a splenectomy or have functional asplenia are at increased risk of fulminant infections with encapsulated bacteria such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis*.^{255,256} The risk of severe infections in asplenic patients is the highest in the first few years after splenectomy when it may be as high as one infection per 14 patient-years, but the risk persists for decades.^{257,258} Sepsis in asplenic patients has a high risk of mortality.²⁵⁹ Asplenic and hyposplenic patients with fever should be evaluated immediately, and empirical antibiotic therapy should be initiated once blood has been drawn for cultures. Patients who are not acutely ill can be treated with ceftriaxone or cefotaxime. More severely ill patients should receive dual therapy with a combination of ceftriaxone or cefotaxime and vancomycin because of concerns for penicillin-resistant pneumococci or β -lactamase-producing *H influenzae*. A combination of moxifloxacin or levofloxacin and vancomycin can be used in patients with allergy to β -lactam antibiotics.

UNIQUE EMERGENCIES RELATED TO SYSTEMIC TUMOR-DIRECTED THERAPY

Cytotoxic chemotherapy has a relatively predictable range of toxicities, most commonly associated with the dose-related cytotoxic effect on normal cells. Cytotoxic chemotherapy can result in life-threatening complications that can present as emergencies, such as thrombotic microangiopathy with mitomycin C and gemcitabine, pulmonary toxicity with bleomycin and gemcitabine, and coronary vasospasms from fluoropyrimidines. Many of the newer targeted agents and immunotherapeutic drugs are associated with unique and sometimes life-threatening toxicities.²⁶⁰ Cardiotoxicity of targeted therapies is increasingly being recognized as a major clinical problem, often with acute presentations.²⁶¹ With the increasing use of immunotherapy for cancer, we are likely to encounter more patients with unusual complications of such therapy. Immunotherapy can adversely affect multiple organs, most commonly the skin, gastrointestinal tract, endocrine system, and lungs, and patients may present in an emergent manner—for example, with adrenal insufficiency or severe diarrhea leading to hypovolemia and shock.²⁶² Newer immunologic technologies such as bispecific antibodies (blinatumomab) or chimeric antigen receptor T cells are frequently associated with serious or life-threatening cytokine release syndrome (CRS).²⁶³ A CRS grading system has been described by Lee et al.²⁶³ Specific therapies such as tocilizumab, an anti-interleukin 6 receptor inhibitor, have efficacy in treating CRS but require experience and judgment as to timing of use to minimize the impairment of efficacy while maximizing safety.

TABLE 11. Indications for the Addition of a Gram-Positive Antibiotic in the Empirical Management of Febrile Neutropenia

Hypotension or hemodynamic instability
Sepsis syndrome
Radiographically documented or strongly suggested pneumonia
Known colonization with methicillin-resistant <i>Staphylococcus aureus</i> , vancomycin-resistant enterococcus, or penicillin-resistant streptococci
Blood cultures positive for gram-positive bacteria
Skin or soft tissue infections
Severe mucositis
Previous use of fluoroquinolones as prophylactic therapy
Suspected catheter-related infection

TABLE 12. Emergencies and Other Urgent Adverse Events Related to Targeted Cancer Therapies

Organ system affected	Class of drug	Example
Cardiovascular		
Congestive heart failure	HER2-directed therapy	Trastuzumab, pertuzumab
	Immunotherapy	Ipilimumab, nivolumab, pembrolizumab
Arterial thromboembolism	VEGF-directed therapy	Bevacizumab, aflibercept, ramucirumab
	Kinase inhibitors	Ponatinib, pazopanib
Venous thromboembolism	Immunomodulatory drugs	Thalidomide, lenalidomide
Arrhythmia	Kinase inhibitors	Dasatinib, vandetanib, ibrutinib, lenvatinib
	Antiemetics	Ondansetron, metoclopramide
	Proteasome inhibitors	Bortezomib, carfilzomib
Pulmonary		
Pneumonitis	mTOR inhibitors	Everolimus, temsirolimus
	Kinase inhibitors	Erlotinib, gefitinib, crizotinib, idelalisib
Pleural effusions	Kinase inhibitors	Dasatinib
Gastrointestinal		
Bowel perforation	VEGF inhibitors	Bevacizumab
Diarhea	Kinase inhibitors	Multiple TKIs
	Immunotherapy	Ipilimumab, nivolumab, pembrolizumab
Acute liver failure	Multiple targeted agents	
Endocrine		
Adrenal insufficiency	Immunotherapy	Ipilimumab, nivolumab, pembrolizumab
Hypophysitis	Immunotherapy	Ipilimumab, nivolumab, pembrolizumab
Hyperglycemia	mTOR inhibitors	Everolimus, temsirolimus
Hematologic		
Hemorrhage	VEGF inhibitors	Bevacizumab, aflibercept, ramucirumab
Neutropenia	Multiple targeted agents	
Thrombocytopenia	Multiple targeted agents	

HER2 = human epidermal growth factor receptor 2; mTOR = mammalian target of rapamycin; TKI = tyrosine kinase inhibitor; VEGF = vascular endothelial growth factor.

A detailed discussion of the emergent toxicities secondary to noncytotoxic systemic therapy is outside the scope of this review. Table 12 lists examples of targeted therapies associated with acute and life-threatening complications.

CONCLUSION

Patients with cancer commonly present with emergent complications of either the malignant disease itself or the therapy they are receiving. Practicing clinicians can therefore expect to encounter such patients in emergency departments or outpatient offices. Prompt evaluation and accurate diagnosis followed by the institution of appropriate therapy can be lifesaving and may prevent irreversible loss of organ function. A sound knowledge of oncological and hematologic emergencies is therefore very important for all health care professionals involved in direct patient care.

Abbreviations and Acronyms: AML = acute myeloid leukemia; ANC = absolute neutrophil count; CNS = central nervous system; CRS = cytokine release syndrome; CT = computed tomography; IV = intravenous; MRI = magnetic resonance imaging; MSSC = malignant spinal cord compression; PTH = parathyroid hormone; PTHrP = PTH-related peptide; RANKL = receptor activator of nuclear factor κ B ligand; SVC = superior vena cava; SVCS = SVC syndrome; TLS = tumor lysis syndrome; WM = Waldenström macroglobulinemia

Correspondence: Address to Thorvardur R. Halfdanarson, MD, Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (halfdanarson.thorvardur@mayo.edu). Individual reprints of this article and a bound reprint of the entire Symposium on Neoplastic Hematology and Medical Oncology will be available for purchase from our website www.mayoclinicproceedings.org.

The Symposium on Neoplastic Hematology and Medical Oncology will continue in an upcoming issue.

REFERENCES

1. Savage P, Sharkey R, Kua T, et al. Clinical characteristics and outcomes for patients with an initial emergency presentation

- of malignancy: a 15 month audit of patient level data. *Cancer Epidemiol.* 2015;39(1):86-90.
2. Stewart AF. Hypercalcemia associated with cancer. *N Engl J Med.* 2005;352(4):373-379.
 3. Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. *Cancer.* 1993; 71(4):1309-1312.
 4. Fahn HJ, Lee YH, Chen MT, Huang JK, Chen KK, Chang LS. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. *J Urol.* 1991;145(2): 248-250.
 5. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality; clinical experience in 126 treated patients. *Ann Intern Med.* 1990; 112(7):499-504.
 6. Ling PJ, A'Hern RP, Hardy JR. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). *Br J Cancer.* 1995;72(1):206-209.
 7. Mallik S, Mallik G, Macabulos ST, Dorigo A. Malignancy associated hypercalcaemia-responsiveness to IV bisphosphonates and prognosis in a palliative population. *Support Care Cancer.* 2016;24(4):1771-1777.
 8. Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. *Clin J Am Soc Nephrol.* 2012;7(10):1722-1729.
 9. Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. *Lancet.* 1992;339(8786): 164-167.
 10. Mundy GR, Edwards JR. PTH-related peptide (PTHrP) in hypercalcemia. *J Am Soc Nephrol.* 2008;19(4):672-675.
 11. Santarpia L, Koch CA, Sarlis NJ. Hypercalcemia in cancer patients: pathobiology and management. *Horm Metab Res.* 2010;42(3):153-164.
 12. Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. *Cancer.* 1994;73(8):2223-2230.
 13. Pecherstorfer M, Schilling T, Blind E, et al. Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. *J Clin Endocrinol Metab.* 1994;78(5): 1268-1270.
 14. Donovan PJ, Achong N, Griffin K, Galligan J, Pretorius CJ, McLeod DS. PTHrP-mediated hypercalcemia: causes and survival in 138 patients. *J Clin Endocrinol Metab.* 2015;100(5): 2024-2029.
 15. Garrett IR, Durie BG, Nedwin GE, et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. *N Engl J Med.* 1987;317(9):526-532.
 16. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. *Blood.* 2000;96(2):671-675.
 17. Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. *Endocr Relat Cancer.* 2005;12(3): 549-583.
 18. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. *J Clin Invest.* 1996; 98(7):1544-1549.
 19. Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. *Blood.* 1993;82(5):1383-1394.
 20. Kallas M, Green F, Hewison M, White C, Kline G. Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review. *J Clin Endocrinol Metab.* 2010;95(7):3111-3117.
 21. Nakajima K, Tamai M, Okaniwa S, et al. Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature. *Endocr J.* 2013;60(5):557-562.
 22. Bushinsky DA, Monk RD. Electrolyte quintet: calcium [published correction appears in *Lancet.* 2002;359(9302):266]. *Lancet.* 1998;352(9124):306-311.
 23. Sternlicht H, Glezeman IG. Hypercalcemia of malignancy and new treatment options. *Ther Clin Risk Manag.* 2015;11: 1779-1788.
 24. Wagner J, Arora S. Oncologic metabolic emergencies. *Emerg Med Clin North Am.* 2014;32(3):509-525.
 25. Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. *Lancet.* 1993;341(8861):1611-1613.
 26. Mundy GR, Guise TA. Hypercalcemia of malignancy. *Am J Med.* 1997;103(2):134-145.
 27. Penel N, Berthon C, Everard F, et al. Prognosis of hypercalcemia in aerodigestive tract cancers: study of 136 recent cases. *Oral Oncol.* 2005;41(9):884-889.
 28. Deftos LJ, First BP. Calcitonin as a drug. *Ann Intern Med.* 1981; 95(2):192-197.
 29. Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. *Calcif Tissue Int.* 1990;46(suppl):S26-S30.
 30. Binstock ML, Mundy GR. Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. *Ann Intern Med.* 1980;93(2):269-272.
 31. Davidson TG. Conventional treatment of hypercalcemia of malignancy. *Am J Health Syst Pharm.* 2001;58(suppl 3):S8-S15.
 32. LeGrand SB, Leskusi D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. *Ann Intern Med.* 2008;149(4):259-263.
 33. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. *J Clin Oncol.* 2001;19(2):558-567.
 34. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. *Am J Med.* 1993;95(3):297-304.
 35. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. *J Clin Oncol.* 1992; 10(1):134-142.
 36. Gucalp R, Theriault R, Gill I, et al. Treatment of cancer-associated hypercalcemia: double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. *Arch Intern Med.* 1994;154(17): 1935-1944.
 37. Pecherstorfer M, Hermann Z, Body JJ, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. *J Clin Oncol.* 1996;14(1):268-276.
 38. Pecherstorfer M, Steinhilber EU, Rizzoli R, Wetterwald M, Bergström B. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. *Support Care Cancer.* 2003; 11(8):539-547.
 39. Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. *Lancet.* 1985; 2(8461):907-910.
 40. Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP Jr. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. *Cancer J.* 2006;12(1): 47-53.
 41. Leyland-Jones B. Treatment of cancer-related hypercalcemia: the role of gallium nitrate. *Semin Oncol.* 2003;30(2 suppl 5): 13-19.
 42. Thosani S, Hu M. Denosumab: a new agent in the management of hypercalcemia of malignancy. *Future Oncol.* 2015; 11(21):2865-2871.

43. Dietzek A, Connelly K, Cotugno M, Bartel S, McDonnell AM. Denosumab in hypercalcemia of malignancy: a case series. *J Oncol Pharm Pract.* 2015;21(2):143-147.
44. Hu MI, Glezeman IG, Leboulloux S, et al. Denosumab for treatment of hypercalcemia of malignancy. *J Clin Endocrinol Metab.* 2014;99(9):3144-3152.
45. Cicci JD, Buie L, Bates J, van Deventer H. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. *Clin Lymphoma Myeloma Leuk.* 2014;14(6):e207-e211.
46. Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. *J Clin Endocrinol Metab.* 2007;92(10):3803-3808.
47. Camus C, Charasse C, Jouannic-Montier I, et al. Calcium free hemodialysis: experience in the treatment of 33 patients with severe hypercalcemia. *Intensive Care Med.* 1996;22(2):116-121.
48. Koo WS, Jeon DS, Ahn SJ, Kim YS, Yoon YS, Bang BK. Calcium-free hemodialysis for the management of hypercalcemia. *Nephron.* 1996;72(3):424-428.
49. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. *N Engl J Med.* 2011;364(19):1844-1854.
50. Will A, Tholouli E. The clinical management of tumour lysis syndrome in haematological malignancies. *Br J Haematol.* 2011;154(1):3-13.
51. Jones GL, Will A, Jackson GH, Webb NJ, Rule S; British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. *Br J Haematol.* 2015;169(5):661-671.
52. Gemici C. Tumour lysis syndrome in solid tumours. *Clin Oncol (R Coll Radiol).* 2006;18(10):773-780.
53. Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. *Br J Haematol.* 2010;149(4):578-586.
54. Howard SC, Trifilio S, Gregory TK, Baxter N, McBride A. Tumour lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. *Ann Hematol.* 2016;95(4):563-573.
55. Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. *Adv Chronic Kidney Dis.* 2014;21(1):18-26.
56. Shimada M, Johnson RJ, May WS Jr, et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. *Nephrol Dial Transplant.* 2009;24(10):2960-2964.
57. Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. *Contrib Nephrol.* 2005;147:61-68.
58. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. *Am J Med.* 1993;94(2):133-139.
59. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. *Br J Haematol.* 2004;127(1):3-11.
60. Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. *Leuk Lymphoma.* 2003;44(1):77-83.
61. Canet E, Zafrani L, Lambert J, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. *PLoS One.* 2013;8(2):e55870.
62. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review [published correction appears in *J Clin Oncol.* 2010;28(4):708]. *J Clin Oncol.* 2008;26(16):2767-2778.
63. Montesinos P, Lorenzo I, Martín G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. *Haematologica.* 2008;93(1):67-74.
64. Mayer MD, Khosravan R, Vemillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. *Am J Ther.* 2005;12(1):22-34.
65. Spina M, Nagy Z, Ribera JM, et al; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. *Ann Oncol.* 2015;26(10):2155-2161.
66. Oldfield V, Perry CM. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. *Drugs.* 2006;66(4):529-545.
67. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAALI (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. *J Clin Oncol.* 2003;21(23):4402-4406.
68. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. *Leukemia.* 2005;19(1):34-38.
69. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. *Blood.* 2001;97(10):2998-3003.
70. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. *J Clin Oncol.* 2010;28(27):4207-4213.
71. Galardy PJ, Hochberg J, Perkins SL, Harrison L, Goldman S, Cairo MS. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report. *Br J Haematol.* 2013;163(3):365-372.
72. Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. *Am J Kidney Dis.* 2013;62(3):481-492.
73. Dinnel J, Moore BL, Skiver BM, Bose P. Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy. *Core Evid.* 2015;10:23-38.
74. Cheuk DK, Chiang AK, Chan GC, Ha SY. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. *Cochrane Database Syst Rev.* 2014;(8):CD006945.
75. Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. *Bone Marrow Transplant.* 2006;37(11):997-1001.
76. Trifilio SM, Pi J, Zook J, et al. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. *Bone Marrow Transplant.* 2011;46(6):800-805.
77. Coutsouvelis J, Wiseman M, Hui L, et al. Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. *Br J Clin Pharmacol.* 2013;75(2):550-553.
78. Feng X, Dong K, Pham D, Pence S, Inciardi J, Bhutana NS. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. *J Clin Pharm Ther.* 2013;38(4):301-308.

79. Tosi P, Barosi G, Luzzaro C, et al. Consensus conference on the management of tumor lysis syndrome. *Haematologica*. 2008;93(12):1877-1885.
80. Sillos EM, Shenep JL, Burghen GA, Pui CH, Behm FG, Sandlund JT. Lactic acidosis: a metabolic complication of hematologic malignancies; case report and review of the literature. *Cancer*. 2001;92(9):2237-2246.
81. Friedenberg AS, Brandoff DE, Schiffman FJ. Type B lactic acidosis as a severe metabolic complication in lymphoma and leukemia: a case series from a single institution and literature review. *Medicine (Baltimore)*. 2007;86(4):225-232.
82. de Groot R, Sprenger RA, Imholz AL, Gerding MN. Type B lactic acidosis in solid malignancies. *Neth J Med*. 2011;69(3):120-123.
83. Kuba H, Inamura T, Ikezaki K, Kawashima M, Fukui M. Thiamine-deficient lactic acidosis with brain tumor treatment: report of three cases. *J Neurosurg*. 1998;89(6):1025-1028.
84. Yoon J, Ahn SH, Lee YJ, Kim CM. Hyponatremia as an independent prognostic factor in patients with terminal cancer. *Support Care Cancer*. 2015;23(6):1735-1740.
85. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. *Support Care Cancer*. 2000;8(3):192-197.
86. Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. *Am J Kidney Dis*. 2012;59(2):222-228.
87. Spinazzé S, Schrijvers D. Metabolic emergencies. *Crit Rev Oncol Hematol*. 2006;58(1):79-89.
88. Flombaum CD. Metabolic emergencies in the cancer patient. *Semin Oncol*. 2000;27(3):322-334.
89. Adrogue HJ, Madias NE. Hyponatremia. *N Engl J Med*. 2000;342(21):1581-1589.
90. Stems RH, Silver SM. Complications and management of hyponatremia. *Curr Opin Nephrol Hypertens*. 2016;25(2):114-119.
91. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. *Am J Med*. 2013;126(10 suppl 1):S1-S42.
92. Mathur A, Gorden P, Libutti SK. Insulinoma. *Surg Clin North Am*. 2009;89(5):1105-1121.
93. Delitala AP, Fanciulli G, Maioli M, Piga G, Delitala G. Primary symptomatic adrenal insufficiency induced by megestrol acetate. *Neth J Med*. 2013;71(1):17-21.
94. Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM. High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate. *J Endocrinol Invest*. 2006;29(2):136-140.
95. Terzolo M, Ardito A, Zaggia B, et al. Management of adjuvant mitotane therapy following resection of adrenal cancer. *Endocrine*. 2012;42(3):521-525.
96. Puar TH, Stikkelbroeck NM, Smans LC, Zelissen PM, Hermus AR. Adrenal crisis: still a deadly event in the 21st century. *Am J Med*. 2016;129(3):339.e1-9.
97. Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. *Semin Thromb Hemost*. 2003;29(5):435-450.
98. García-Sanz R, Montoto S, Torrequera A, et al; Spanish Group for the Study of Waldenström Macroglobulinaemia and PETHEMA (Programme for the Study and Treatment of Haematological Malignancies). Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. *Br J Haematol*. 2001;115(3):575-582.
99. Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. *Blood*. 2012;119(10):2205-2208.
100. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clin Proc*. 2003;78(1):21-33.
101. Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. *Semin Thromb Hemost*. 2003;29(5):467-471.
102. Kwaan HC. Hyperviscosity in plasma cell dyscrasias. *Clin Hemorheol Microcirc*. 2013;55(1):75-83.
103. Crawford J, Cox EB, Cohen HJ. Evaluation of hyperviscosity in monoclonal gammopathies. *Am J Med*. 1985;79(1):13-22.
104. MacKenzie MR, Lee TK. Blood viscosity in Waldenström macroglobulinemia. *Blood*. 1977;49(4):507-510.
105. Zarkovic M, Kwaan HC. Correction of hyperviscosity by apheresis. *Semin Thromb Hemost*. 2003;29(5):535-542.
106. Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocytosis, leukostasis and leukapheresis: practice management. *Blood Rev*. 2012;26(3):117-122.
107. Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. *Blood*. 2015;125(21):3246-3252.
108. Ruggiero A, Rizzo D, Amato M, Riccardi R. Management of hyperleukocytosis. *Curr Treat Options Oncol*. 2016;17(2):7.
109. Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. *Leuk Lymphoma*. 2000;39(1-2):1-18.
110. Adams BD, Baker R, Lopez JA, Spencer S. Myeloproliferative disorders and the hyperviscosity syndrome. *Hematol Oncol Clin North Am*. 2010;24(3):585-602.
111. McKee LC Jr, Collins RD. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. *Medicine (Baltimore)*. 1974;53(6):463-478.
112. Stucki A, Rivier AS, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. *Blood*. 2001;97(7):2121-2129.
113. Marbello L, Ricci F, Nosari AM, et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. *Leuk Res*. 2008;32(8):1221-1227.
114. Harris AL. Leukostasis associated with blood transfusion in acute myeloid leukaemia. *Br Med J*. 1978;1(6121):1169-1171.
115. Oberoi S, Lehmebecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. *Leuk Res*. 2014;38(4):460-468.
116. Pastore F, Pastore A, Wittmann G, Hiddemann W, Spiekermann K. The role of therapeutic leukapheresis in hyperleukocytotic AML. *PLoS One*. 2014;9(4):e95062.
117. Aqai N, O'Doherty U. Leukocytapheresis for the treatment of hyperleukocytosis secondary to acute leukemia. *Hematology Am Soc Hematol Educ Program*. 2014;2014(1):457-460.
118. Pham HP, Schwartz J. How we approach a patient with symptoms of leukostasis requiring emergent leukocytapheresis. *Transfusion*. 2015;55(10):2306-2311.
119. Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. *J Clin Apher*. 2013;28(3):145-284.
120. Bach F, Larsen BH, Rohde K, et al. Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. *Acta Neurochir (Wien)*. 1990;107(1-2):37-43.
121. Loblaw DA, Laperriere NJ, Mackillop WJ. A population-based study of malignant spinal cord compression in Ontario. *Clin Oncol (R Coll Radiol)*. 2003;15(4):211-217.
122. Mak KS, Lee LK, Mak RH, et al. Incidence and treatment patterns in hospitalizations for malignant spinal cord compression in the United States, 1998-2006. *Int J Radiat Oncol Biol Phys*. 2011;80(3):824-831.
123. Loblaw DA, Smith K, Lockwood G, Laperriere N. The Princess Margaret Hospital experience of malignant spinal cord compression. *Proc Am Soc Clin Oncol*. 2003;22:119. Abstract 477.

124. Helweg-Larsen S, Sørensen PS, Kreiner S. Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. *Int J Radiat Oncol Biol Phys*. 2000; 46(5):1163-1169.
125. Kim RY, Spencer SA, Meredith RF, et al. Extradural spinal cord compression: analysis of factors determining functional prognosis—prospective study. *Radiology*. 1990;176(1):279-282.
126. Rades D, Heidenreich F, Karstens JH. Final results of a prospective study of the prognostic value of the time to develop motor deficits before irradiation in metastatic spinal cord compression. *Int J Radiat Oncol Biol Phys*. 2002;53(4):975-979.
127. Cole JS, Patchell RA. Metastatic epidural spinal cord compression. *Lancet Neurol*. 2008;7(5):459-466.
128. Constans JP, de Dvitiis E, Donzelli R, Spaziante R, Meder JF, Haye C. Spinal metastases with neurological manifestations: review of 600 cases. *J Neurosurg*. 1983;59(1):111-118.
129. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. *Cancer*. 1982;49(4):759-772.
130. Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. *Ann Neurol*. 1978;3(1):40-51.
131. Sutcliffe P, Connock M, Shyangdan D, Court R, Kandala NB, Clarke A. A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression. *Health Technol Assess*. 2013;17(42):1-274.
132. Helweg-Larsen S, Sørensen PS. Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. *Eur J Cancer*. 1994;30A(3):396-398.
133. Levack P, Graham J, Collie D, et al; Scottish Cord Compression Study Group. Don't wait for a sensory level—listen to the symptoms: a prospective audit of the delays in diagnosis of malignant cord compression. *Clin Oncol (R Coll Radiol)*. 2002;14(6):472-480.
134. Schiff D, O'Neill BP, Suman VJ. Spinal epidural metastasis as the initial manifestation of malignancy: clinical features and diagnostic approach. *Neurology*. 1997;49(2):452-456.
135. Downie A, Williams CM, Henschke N, et al. Red flags to screen for malignancy and fracture in patients with low back pain: systematic review [published correction appears in *BMJ*. 2014;348:g7]. *BMJ*. 2013;347:f7095.
136. Henschke N, Maher CG, Ostelo RW, de Vet HC, Macaskill P, Irwig L. Red flags to screen for malignancy in patients with low-back pain. *Cochrane Database Syst Rev*. 2013;(2):CD008686.
137. Savage P, Sharkey R, Kua T, et al. Malignant spinal cord compression: NICE guidance, improvements and challenges. *QJM*. 2014;107(4):277-282.
138. Hainline B, Tuszynski MH, Posner JB. Ataxia in epidural spinal cord compression. *Neurology*. 1992;42(11):2193-2195.
139. Li KC, Poon PY. Sensitivity and specificity of MRI in detecting malignant spinal cord compression and in distinguishing malignant from benign compression fractures of vertebrae. *Magn Reson Imaging*. 1988;6(5):547-556.
140. Loughrey GJ, Collins CD, Todd SM, Brown NM, Johnson RJ. Magnetic resonance imaging in the management of suspected spinal canal disease in patients with known malignancy. *Clin Radiol*. 2000;55(11):849-855.
141. Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. *J Clin Oncol*. 2005;23(9):2028-2037.
142. National Institute for Health and Clinical Excellence. Metastatic spinal cord compression in adults: risk assessment, diagnosis, and management, Clinical Guideline 75. National Institute for Health and Clinical Excellence website. www.nice.org.uk/CG75. Published November 2008. Accessed February 7, 2016.
143. Husband DJ, Grant KA, Romaniuk CS. MRI in the diagnosis and treatment of suspected malignant spinal cord compression. *Br J Radiol*. 2001;74(877):15-23.
144. Cook AM, Lau TN, Tomlinson MJ, Vaidya M, Wakeley CJ, Goddard P. Magnetic resonance imaging of the whole spine in suspected malignant spinal cord compression: impact on management. *Clin Oncol (R Coll Radiol)*. 1998; 10(1):39-43.
145. Helweg-Larsen S, Hansen SW, Sørensen PS. Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. *Int J Radiat Oncol Biol Phys*. 1995;33(3):595-598.
146. Schiff D, O'Neill BP, Wang CH, O'Fallon JR. Neuroimaging and treatment implications of patients with multiple epidural spinal metastases. *Cancer*. 1998;83(8):1593-1601.
147. van der Sande JJ, Kröger R, Boogerd W. Multiple spinal epidural metastases: an unexpectedly frequent finding. *J Neurol Neurosurg Psychiatry*. 1990;53(11):1001-1003.
148. Metser U, Lerman H, Blank A, Lievshitz G, Bokstein F, Even-Sapir E. Malignant involvement of the spine: assessment by ¹⁸F-FDG PET/CT. *J Nucl Med*. 2004;45(2):279-284.
149. Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. *Int J Radiat Oncol Biol Phys*. 1995;32(4):959-967.
150. Rades D, Fehlauer F, Schulte R, et al. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. *J Clin Oncol*. 2006;24(21):3388-3393.
151. Sørensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. *Eur J Cancer*. 1994;30A(1):22-27.
152. Vecht CJ, Haaxma-Reiche H, van Putten WL, de Visser M, Vries EP, Twijnstra A. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. *Neurology*. 1989;39(9):1255-1257.
153. Graham PH, Capp A, Delaney G, et al. A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex study. *Clin Oncol (R Coll Radiol)*. 2006;18(1):70-76.
154. Heimdal K, Hirschberg H, Slettebø H, Watne K, Nome O. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. *J Neurooncol*. 1992;12(2):141-144.
155. George R, Jeba J, Ramkumar G, Chacko AG, Tharyan P. Interventions for the treatment of metastatic extradural spinal cord compression in adults. *Cochrane Database Syst Rev*. 2015;(9):CD006716.
156. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. *Lancet*. 2005; 366(9486):643-648.
157. Chi JH, Gokaslan Z, McCormick P, Tibbs PA, Kryscio RJ, Patchell RA. Selecting treatment for patients with malignant epidural spinal cord compression—does age matter? results from a randomized clinical trial. *Spine (Phila Pa 1976)*. 2009; 34(5):431-435.
158. Rades D, Huttenlocher S, Dunst J, et al. Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. *J Clin Oncol*. 2010;28(22):3597-3604.
159. Rades D, Rudat V, Veninga T, et al. A score predicting post-treatment ambulatory status in patients irradiated for metastatic spinal cord compression. *Int J Radiat Oncol Biol Phys*. 2008; 72(3):905-908.

160. Rades D, Stalpers LJ, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. *J Clin Oncol*. 2005;23(15):3366-3375.
161. Prewett S, Venkitaraman R. Metastatic spinal cord compression: review of the evidence for a radiotherapy dose fractionation schedule. *Clin Oncol (R Coll Radiol)*. 2010;22(3):222-230.
162. Rades D, Lange M, Veninga T, et al. Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. *Int J Radiat Oncol Biol Phys*. 2011;79(2):524-530.
163. Maranzano E, Trippa F, Casale M, et al. 8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. *Radiother Oncol*. 2009;93(2):174-179.
164. Maranzano E, Bellavita R, Rossi R, et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. *J Clin Oncol*. 2005;23(15):3358-3365.
165. Laufer I, Iorgulescu JB, Chapman T, et al. Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. *J Neurosurg Spine*. 2013;18(3):207-214.
166. Ryu S, Rock J, Jain R, et al. Radiosurgical decompression of metastatic epidural compression. *Cancer*. 2010;116(9):2250-2257.
167. Ryu S, Yoon H, Stessin A, Gutman F, Rosiello A, Davis R. Contemporary treatment with radiosurgery for spine metastasis and spinal cord compression in 2015. *Radiat Oncol J*. 2015;33(1):1-11.
168. Lin X, DeAngelis LM. Treatment of brain metastases. *J Clin Oncol*. 2015;33(30):3475-3484.
169. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. *J Neurooncol*. 2005;75(1):5-14.
170. Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. *Neurosurg Clin N Am*. 2011;22(1):1-6v.
171. Nussbaum ES, Djililian HR, Cho KH, Hall WA. Brain metastases: histology, multiplicity, surgery, and survival. *Cancer*. 1996;78(8):1781-1788.
172. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneaun FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. *J Clin Oncol*. 2004;22(14):2865-2872.
173. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases—translation to new therapies. *Nat Rev Clin Oncol*. 2011;8(6):344-356.
174. Tosoni A, Emmani M, Brandes AA. The pathogenesis and treatment of brain metastases: a comprehensive review. *Crit Rev Oncol Hematol*. 2004;52(3):199-215.
175. Kaal EC, Vecht CJ. The management of brain edema in brain tumors. *Curr Opin Oncol*. 2004;16(6):593-600.
176. Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Gonçalves A. Recent trends in epidemiology of brain metastases: an overview. *Anticancer Res*. 2012;32(11):4655-4662.
177. Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. *Neurology*. 1993;43(9):1678-1683.
178. Schaefer PW, Budzik RF Jr, Gonzalez RG. Imaging of cerebral metastases. *Neurosurg Clin N Am*. 1996;7(3):393-423.
179. Sze G, Milano E, Johnson C, Heier L. Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. *AJNR Am J Neuroradiol*. 1990;11(4):785-791.
180. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. *J Clin Oncol*. 2012;30(4):419-425.
181. Soffietti R, Comu P, Delattre JY, et al. EFNS guidelines on diagnosis and treatment of brain metastases: report of an EFNS task force. *Eur J Neurol*. 2006;13(7):674-681.
182. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. *Neurology*. 1994;44(4):675-680.
183. Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol*. 2010;96(1):103-114.
184. Cohen N, Strauss G, Lew R, Silver D, Recht L. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? a retrospective analysis. *J Clin Oncol*. 1988;6(10):1621-1624.
185. Mikkelsen T, Paleologos NA, Robinson PD, et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol*. 2010;96(1):97-102.
186. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2000;54(10):1886-1893.
187. Tremont-Lukats IV, Ratilal BO, Armstrong T, Gilbert MR. Anti-epileptic drugs for preventing seizures in people with brain tumors. *Cochrane Database Syst Rev*. 2008;(2):CD004424.
188. Sirven JI, Wingerchuk DM, Dratzkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis. *Mayo Clin Proc*. 2004;79(12):1489-1494.
189. Betjemann JP, Lowenstein DH. Status epilepticus in adults. *Lancet Neurol*. 2015;14(6):615-624.
190. Jenkinson MD, Haylock B, Shenoy A, Husband D, Javadpour M. Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. *Eur J Cancer*. 2011;47(5):649-655.
191. Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease. *Prog Cardiovasc Dis*. 2010;53(2):157-163.
192. Lestuzzi C, Berretta M, Tomkowski W. 2015 Update on the diagnosis and management of neoplastic pericardial disease. *Expert Rev Cardiovasc Ther*. 2015;13(4):377-389.
193. Spodick DH. Acute cardiac tamponade. *N Engl J Med*. 2003;349(7):684-690.
194. Roy CL, Minor MA, Brookhart MA, Choudhry NK. Does this patient with a pericardial effusion have cardiac tamponade? *JAMA*. 2007;297(16):1810-1818.
195. Goyal M, Woods KM, Atwood JE. Electrical alternans: a sign, not a diagnosis. *South Med J*. 2013;106(8):485-489.
196. Wann S, Passen E. Echocardiography in pericardial disease. *J Am Soc Echocardiogr*. 2008;21(1):7-13.
197. Lopez Costa I, Bhalla S. Computed tomography and magnetic resonance imaging of the pericardium [published correction appears in *Semin Roentgenol*. 2008;43(4):337]. *Semin Roentgenol*. 2008;43(3):234-245.
198. Tsang TS, Enriquez-Sarano M, Freeman WK, et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. *Mayo Clin Proc*. 2002;77(5):429-436.
199. Virk SA, Chandrakumar D, Villanueva C, Wolfenden H, Liou K, Cao C. Systematic review of percutaneous interventions for malignant pericardial effusion. *Heart*. 2015;101(20):1619-1626.
200. Jama GM, Scarci M, Bowden J, Marciniak SJ. Palliative treatment for symptomatic malignant pericardial effusion. *Interact Cardiovasc Thorac Surg*. 2014;19(6):1019-1026.
201. Lepper PM, Ott SR, Hoppe H, et al. Superior vena cava syndrome in thoracic malignancies. *Respir Care*. 2011;56(5):653-666.

202. Wilson LD, Detterbeck FC, Yahalom J. Superior vena cava syndrome with malignant causes [published correction appears in *N Engl J Med*. 2008;358(10):1083]. *N Engl J Med*. 2007;356(18):1862-1869.
203. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. *Medicine (Baltimore)*. 2006;85(1):37-42.
204. Bertrand M, Mesant CA, Klein L, Scott E. Iatrogenic superior vena cava syndrome: a new entity. *Cancer*. 1984;54(2):376-378.
205. Stanford W, Jolles H, Ell S, Chiu LC. Superior vena cava obstruction: a venographic classification. *AJR Am J Roentgenol*. 1987;148(2):259-262.
206. Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome—a proposed classification system and algorithm for management. *J Thorac Oncol*. 2008;3(8):811-814.
207. Wan JF, Bezjak A. Superior vena cava syndrome. *Hematol Oncol Clin North Am*. 2010;24(3):501-513.
208. Schraufnagel DE, Hill R, Leech JA, Pare JA. Superior vena caval obstruction: is it a medical emergency? *Am J Med*. 1981;70(6):1169-1174.
209. Yellin A, Rosen A, Reichert N, Lieberman Y. Superior vena cava syndrome: the myth—the facts. *Am Rev Respir Dis*. 1990;141(5 pt 1):1114-1118.
210. Rachapalli V, Boucher LM. Superior vena cava syndrome: role of the interventionalist. *Can Assoc Radiol J*. 2014;65(2):168-176.
211. Ganeshan A, Hon LQ, Warakaulle DR, Morgan R, Uberoi R. Superior vena caval stenting for SVC obstruction: current status. *Eur J Radiol*. 2009;71(2):343-349.
212. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. *Clin Oncol (R Coll Radiol)*. 2002;14(5):338-351.
213. Kee ST, Kinoshita L, Razavi MK, Nyman UR, Semba CP, Dake MD. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. *Radiology*. 1998;206(1):187-193.
214. Chhajed PN, Baty F, Pless M, Somandin S, Tamm M, Brutsche MH. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction. *Chest*. 2006;130(6):1803-1807.
215. Chen K, Varon J, Wenker OC. Malignant airway obstruction: recognition and management. *J Emerg Med*. 1998;16(1):83-92.
216. Theodore PR. Emergent management of malignancy-related acute airway obstruction. *Emerg Med Clin North Am*. 2009;27(2):231-241.
217. Murgu S, Egressy K, Laxmanan B, Doblare G, Ortiz-Comino R, Hogarth DK. Central airway obstruction: benign strictures, tracheobronchomalacia and malignancy-related obstruction. *Chest*. 2016;150(2):426-441.
218. Gorden JA, Ernst A. Endoscopic management of central airway obstruction. *Semin Thorac Cardiovasc Surg*. 2009;21(3):263-273.
219. Ost DE, Ernst A, Grosu HB, et al; AQuIRE Bronchoscopy Registry. Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. *Chest*. 2015;147(5):1282-1298.
220. Grosu HB, Eapen GA, Morice RC, et al. Stents are associated with increased risk of respiratory infections in patients undergoing airway interventions for malignant airways disease. *Chest*. 2013;144(2):441-449.
221. Agrafiotis M, Siempos II, Falagas ME. Infections related to airway stenting: a systematic review. *Respiration*. 2009;78(1):69-74.
222. Crocco JA, Rooney JJ, Fankushen DS, DiBenedetto RJ, Lyons HA. Massive hemoptysis. *Arch Intern Med*. 1968;121(6):495-498.
223. Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. *Chest*. 1997;112(2):440-444.
224. Jean-Baptiste E. Clinical assessment and management of massive hemoptysis. *Crit Care Med*. 2000;28(5):1642-1647.
225. Yendamuri S. Massive airway hemorrhage. *Thorac Surg Clin*. 2015;25(3):255-260.
226. Noë GD, Jaffé SM, Molan MP. CT and CT angiography in massive haemoptysis with emphasis on pre-embolization assessment. *Clin Radiol*. 2011;66(9):869-875.
227. Khalil A, Parrot A, Nedelcu C, Fartoukh M, Marsault C, Carette MF. Severe hemoptysis of pulmonary arterial origin: signs and role of multidetector row CT angiography. *Chest*. 2008;133(1):212-219.
228. Meijer K, de Graaff WE, Daenen SM, van der Meer J. Successful treatment of massive hemoptysis in acute leukemia with recombinant factor VIIa [letter]. *Arch Intern Med*. 2000;160(14):2216-2217.
229. Wheeler MJ, Mead GM, Bhandari S, Fennell J. Recombinant factor VIIa in the management of pulmonary hemorrhage associated with metastatic choriocarcinoma. *J Clin Oncol*. 2008;26(6):1008-1010.
230. Chun JY, Morgan R, Belli AM. Radiological management of hemoptysis: a comprehensive review of diagnostic imaging and bronchial arterial embolization. *Cardiovasc Intervent Radiol*. 2010;33(2):240-250.
231. Fruchter O, Schner S, Rusanov V, Belenky A, Kramer MR. Bronchial artery embolization for massive hemoptysis: long-term follow-up. *Asian Cardiovasc Thorac Ann*. 2015;23(1):55-60.
232. Cremaschi P, Nascimbene C, Vitulo P, et al. Therapeutic embolization of bronchial artery: a successful treatment in 209 cases of relapse hemoptysis. *Angiology*. 1993;44(4):295-299.
233. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2011;52(4):e56-e93.
234. Klastersky J, de Naurois J, Rolston K, et al; ESMO Guidelines Committee. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2016;27(suppl 5):v111-v118.
235. Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. 2013;31(6):794-810.
236. Holland T, Fowler VG Jr, Shelburne SA III. Invasive gram-positive bacterial infection in cancer patients. *Clin Infect Dis*. 2014;59(suppl 5):S331-S334.
237. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. *Clin Infect Dis*. 2003;36(9):1103-1110.
238. Trearich EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. *Curr Opin Infect Dis*. 2014;27(2):200-210.
239. Gudiol C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. *Clin Microbiol Infect*. 2013;19(5):474-479.
240. Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. *J Clin Oncol*. 1999;17(3):796-805.
241. Wu CW, Wu JY, Chen CK, et al. Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? a systematic review and meta-analysis. *Support Care Cancer*. 2015;23(10):2863-2872.

242. Ahn S, Lee YS, Lee JL, Lim KS, Yoon SC. A new prognostic model for chemotherapy-induced febrile neutropenia. *Int J Clin Oncol*. 2016;21(1):46-52.
243. Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. *Antimicrob Agents Chemother*. 2014;58(7):3799-3803.
244. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. *Crit Care Med*. 2010;38(4):1045-1053.
245. Keng MK, Thallner EA, Elson P, et al. Reducing time to antibiotic administration for febrile neutropenia in the emergency department. *J Oncol Pract*. 2015;11(6):450-455.
246. Lim C, Bawden J, Wing A, et al. Febrile neutropenia in EDs: the role of an electronic clinical practice guideline. *Am J Emerg Med*. 2012;30(1):5-11. doi:10.1016/j.ajem.2011.11.011.
247. Vidal L, Ben Dor I, Paul M, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. *Cochrane Database Syst Rev*. 2013;(10):CD003992.
248. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. *J Clin Oncol*. 2000;18(16):3038-3051.
249. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: prevention and treatment of cancer-related infections. Version 1.2016. National Comprehensive Cancer Network website. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. Accessed February 21, 2017.
250. Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. *J Clin Oncol*. 2015;33(5):465-471.
251. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. *N Engl J Med*. 1999;341(5):305-311.
252. Kem WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H; International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. *N Engl J Med*. 1999;341(5):312-318.
253. Mhaskar R, Clark OA, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. *Cochrane Database Syst Rev*. 2014;(10):CD003039.
254. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2015;33(28):3199-3212.
255. Rubin LG, Schaffner W. Care of the asplenic patient. *N Engl J Med*. 2014;371(4):349-356.
256. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. *Lancet*. 2011;378(9785):86-97.
257. Kyaw MH, Holmes EM, Toolis F, et al. Evaluation of severe infection and survival after splenectomy. *Am J Med*. 2006;119(3):276.e1-7.
258. Cullingford GL, Watkins DN, Watts AD, Mallon DF. Severe late postsplenectomy infection. *Br J Surg*. 1991;78(6):716-721.
259. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. *J Infect*. 2001;43(3):182-186.
260. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. *CA Cancer J Clin*. 2013;63(4):249-279.
261. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. *N Engl J Med*. 2016;375(15):1457-1467.
262. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. *JAMA Oncol*. 2016;2(10):1346-1353.
263. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in *Blood*. 2015;126(8):1048]. *Blood*. 2014;124(2):188-195.